

This is a self-archived – parallel-published version of an original article. This version may differ from the original in pagination and typographic details. When using please cite the original.

AUTHOR Akhrass Hussein, Conway James RW, Kronqvist Pauliina, Kallionpää Roosa E, Oliveira-Ferrer Leticia, Cervero Pasquale, Linder Stefan, Aepfelbacher Martin, Zauber Henrik, Rae James, Parton Robert G, Disanza Andrea, Scita Giorgio, Mayor Satyajit, Selbach Matthias, Veltel Stefan, Ivaska Johanna

TITLE Cargo-specific recruitment in clathrin- and dynamin-independent endocytosis

YEAR 2021, Oct. 06

DOI <https://doi.org/10.1038/s41556-021-00767-x>

VERSION Final draft (AAM)

CITATION Moreno-Layseca, P., Jääntti, N.Z., Godbole, R. *et al.* Cargo-specific recruitment in clathrin- and dynamin-independent endocytosis. *Nat Cell Biol* **23**, 1073–1084 (2021).
<https://doi.org/10.1038/s41556-021-00767-x>

1 **Cargo-specific recruitment in clathrin- and dynamin-independent** 2 **endocytosis**

3
4 Paulina Moreno-Layseca^{1,2}, Niklas Z. Jääntti¹, Rashmi Godbole^{3,4}, Christian Sommer⁵,
5 Guillaume Jacquemet^{1,6}, Hussein Al-Akhrass¹, James R. W. Conway¹, Pauliina Kronqvist⁷,
6 Roosa E. Kallionpää⁸, Leticia Oliveira-Ferrer², Pasquale Cervero², Stefan Linder², Martin
7 Aepfelbacher², Henrik Zauber⁵, James Rae⁹, Robert G. Parton^{9,10}, Andrea Disanza¹¹, Giorgio
8 Scita¹¹, Satyajit Mayor³, Matthias Selbach⁵, Stefan Veltel^{2,12*}, Johanna Ivaska^{1,13,14*}

9 ¹Turku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku,
10 Finland.

11 ²University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany.

12 ³National Centre for Biological Science (TIFR), Bellary Road, Bangalore, 560065, India.

13 ⁴The university of Trans-Disciplinary Health Sciences and Technology (TDU), Yelahanka, Bangalore,
14 560064, India.

15 ⁵Max-Delbrück-Centrum für Molekulare Medizin (MDC), 13092 Berlin, Germany.

16 ⁶Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, 20520 Turku, Finland.

17 ⁷Institute of Biomedicine, Faculty of Medicine, University of Turku, FI-20520 Turku, Finland.

18 ⁸Auria Biobank, Turku University Hospital and University of Turku, FI-20520 Turku, Finland.

19 ⁹Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia

20 ¹⁰Centre for Microscopy and Microanalysis, University of Queensland, Brisbane, QLD, 4072,
21 Australia.

22 ¹¹IFOM, Fondazione Istituto FIRC di Oncologia Molecolare and University of Milan, Milan, 20139,
23 Italy.

24 ¹²Hochschule Bremen, City University of Applied Sciences, 28199 Bremen, Germany.

25 ¹³Department of Life Sciences, University of Turku, FI-20520 Turku, Finland.

26 ¹⁴InFLAMES Research Flagship Center, University of Turku

27
28
29 ***Correspondence to:** Johanna.Ivaska@utu.fi; Stefan.Veltel@hs-bremen.de

30 **Abstract:**

31 Spatially controlled, cargo-specific endocytosis is essential for development, tissue
32 homeostasis and cancer invasion. Unlike the cargo-specific clathrin-mediated endocytosis,
33 the clathrin- and dynamin-independent endocytic pathway (CLIC-GEEC, CG-pathway) is
34 considered a bulk internalization route for the fluid phase, glycosylated membrane proteins
35 and lipids. While the core molecular players of CG-endocytosis have been recently defined,
36 evidence of cargo-specific adaptors or selective uptake of proteins for the pathway are
37 lacking. Here we identify the actin-binding protein Swiprosin-1 (Swip1, EFHD2) as a cargo-
38 specific adaptor for CG-endocytosis. Swip1 couples active Rab21-associated integrins with
39 key components of the CG-endocytic machinery: Arf1, IRSp53 and actin, and is critical for
40 integrin endocytosis. Through this function, Swip1 supports integrin-dependent cancer cell
41 migration and invasion and is a negative prognostic marker in breast cancer. Our results
42 demonstrate a previously unknown cargo selectivity for the CG-pathway and a role for
43 specific adaptors in recruitment into this endocytic route.

44

45

46 Endocytosis is a vital process involving the internalization of extracellular material and cell
47 surface receptors. This controls various functions ranging from fluid-phase nutrient uptake
48 and spatially and temporally regulated traffic of adhesion and growth factor receptors, to
49 pathogen entry¹. The predominant view is that the specificity of endocytosis is achieved
50 through cargo-specific adaptors, as described for clathrin-mediated endocytosis (CME)^{2,3}.
51 This raises the possibility that as-yet unidentified cargo adaptor proteins could function as
52 key gatekeepers for other endosomal routes.

53 The CG-pathway internalizes a major fraction of the extracellular fluid phase,
54 glycosylphosphatidylinositol (GPI)-anchored proteins and other cell surface receptors,
55 including nutrient transporters, ion channels and cell adhesion receptors^{4,5}, as well as
56 bacterial and viral pathogens^{4,6}. This occurs through high-capacity tubulovesicular membrane
57 uptake carriers called CLICs (clathrin-independent carriers)^{7,8}. CLICs are formed via the
58 recruitment of Arf1, actin-binding BAR-domain protein IRSp53 and Arp2/3 to the
59 membrane, followed by Cdc42 activation of IRSp53 and Arp2/3-mediated actin
60 polymerization, presumptively resulting in the scission of CLICs and generation of CG
61 endosomes⁹. Although the core machinery of CG-endocytosis has been defined, no cargo-
62 specific adaptors are known¹⁰.

63 The small GTPase Rab21 binds directly to integrins to regulate endo/exosomal traffic,
64 cytokinesis, chromosome integrity, endosomal signaling and anoikis¹¹⁻¹⁴. Rab21 interacts
65 with integrins independently of its activation state (GDP/GTP); nevertheless, integrin
66 endocytosis requires Rab21 activity, but the exact mechanism is currently unknown¹¹. In
67 addition, very few Rab21 interactors have been identified¹⁵.

68 Here, we identify Swip1 (EFHD2) as an interactor of Rab21 and a cargo-specific adaptor for
69 CG-endocytosis.

70 **Results:**

71 **Swip1 interacts with Rab21 and β 1-integrin.**

72 To identify Rab21-interacting proteins, we performed proteomic analyses by stable isotope
73 labelling with amino acids in cell culture (SILAC) of Rab21 wild-type (WT), Rab21^{Q76L}
74 active mutant (CA-Rab21) or Rab21^{T31N} inactive mutant (DN-Rab21) expressing cells^{16,17}.
75 This mass spectrometry (MS) strategy identified the actin-binding protein Swip1 as a putative
76 active Rab21 interactor (Fig. 1a, Extended Data Fig. 1a-d, Supplementary Table 1). GFP
77 pulldowns from cell lysate demonstrated endogenous Swip1 binding preferably to WT and
78 CA-Rab21, and not to the closely related Rab5 GTPase (Fig. 1b, Extended Data Fig. 1e).
79 Moreover, purified recombinant GST-Swip1 interacted directly with GTP-analog loaded
80 recombinant Rab21 (positive control: Rab21-GTP specific interactor APPL1^{18,19}; Fig. 1c).
81 We next validated the interaction in cells, where Swip1 localized to GFP-Rab21-containing
82 endosomes (Fig. 2a) and proximity ligation assay (PLA) indicated endogenous Swip1 and
83 Rab21 association in intact cells (Fig. 2b). Rab21 localizes with membrane-proximal puncta
84 and early endosomes positive for endocytosed active β 1-integrins^{11,14,20}. Concordantly,
85 bimolecular fluorescence complementation (BiFC)²¹ revealed Swip1 and Rab21 interaction in
86 structures overlapping predominantly with EEA1, Rab5 and VPS35 and to a lesser extent
87 with late endosome markers (Extended Data Fig. 2a-c). Furthermore, Swip1 localized to
88 Rab21-positive, β 1-integrin-containing endosomes (Extended Data Fig. 3a). These data
89 indicate that Swip1 interacts with integrin-associated Rab21 in cells.

90 Total internal reflection fluorescence (TIRF) microscopy of endocytic events on the plasma
91 membrane revealed V1-Rab21/V2-Swip1 complexes moving at the cell-ECM interface in
92 live cells^{9,22} (Fig. 2c). The BiFC interaction puncta were dynamic, detected at the cell
93 periphery and in the cell center, and were absent in Venus-expressing control cells
94 (Supplementary Video 1). Structured illumination microscopy (SIM) images of the cell-ECM

95 interface revealed that Swip1, Rab21 and β 1-integrin-positive structures extended vertically
96 into the cell (Fig. 2d-e, x-z projections, Extended Data Fig. 3b). In these structures, Swip1 co-
97 localized significantly more with Rab21 than Rab5, Rab7 and Rab11 (Extended Data Fig.
98 3c), indicating a degree of specificity for Rab21 binding. Together, these data identify Swip1
99 as an interactor of active Rab21, overlapping with β 1-integrins in endosomal compartments
100 and in close proximity with the plasma membrane.

101

102 **Swip1 associates with CG-pathway components**

103 Interestingly, Arf1 was detected as an active Rab21 interactor alongside Swip1 (Fig. 1a,
104 Extended Data Fig. 1a-d) prompting us to test whether Rab21 and/or Swip1 associate with
105 Arf1. Arf1 is a known regulator of CG-endocytosis, where cargo uptake is mediated by
106 tubulovesicular membrane invaginations²³. Both GFP-Rab21 and GFP-Swip1 co-
107 immunoprecipitated with endogenous Arf1 (Fig. 3a). In addition, another CG-endocytosis
108 regulator, IRSp53¹⁰, was also detected in the GFP-immunoprecipitations (Fig. 3a) and
109 immunoprecipitation of endogenous IRSp53 co-precipitated endogenous Swip1 and Arf1
110 (Fig. 3b). Moreover, significant PLA signal between IRSp53 and active β 1-integrin (12G10
111 active-integrin conformation-specific antibody) showed close proximity of the endogenous
112 proteins (Fig. 3c). These data indicate that the Rab21- β 1-integrin-Swip1 complex is
113 associated with the CG-endocytosis machinery. To investigate this in more detail, we imaged
114 Swip1 co-localization with known components of CME, caveolin-mediated endocytosis and
115 CG-endocytosis using SIM. Swip1 co-localized significantly more with Rab21, Arf1 and
116 IRSp53 than with clathrin, the clathrin adaptor AP2, caveolin or dynamin2 (Fig. 3d-e). These
117 data are consistent with Rab21-mediated integrin endocytosis remaining unaffected by
118 clathrin inhibition¹², the clathrin and caveolin endocytic pathway components not being
119 enriched in the active Rab21 MS-fractions (Fig. 1a, Extended Data Fig. 1a-d) and with the
120 absence of dynamin I/II in bimolecular complementation affinity purified (BiCAP)²¹ V1-

121 Rab21 and V2-Swip1 complexes in cells (Fig. 3f). Furthermore, using another super-
122 resolution microscopy technique DNA-PAINT²⁴ (Extended Data Fig. 4a) we detected ring-
123 like structures of GFP-Swip1 co-localizing with Arf1-HA at the TIRF plane. Moreover,
124 Rab21/Swip1-BiFC puncta were detected dynamically moving towards IRSp53-positive
125 structures before disappearing from the TIRF plane in live cells (Fig. 3g, Supplementary
126 Video 2). These data indicate the existence of a Swip1/Rab21-GTP complex that links to the
127 CG-endocytosis machinery.

128

129 **Swip1-regulated endocytosis of active β 1-integrins is Rab21 dependent**

130 We next investigated the requirement for Swip1 for integrin endocytosis. Silencing of Swip1
131 decreased the uptake of cell surface-labelled active β 1-integrin in MDA-MB-231 cells. Swip1
132 silencing-induced inhibition of integrin endocytosis was apparent at the 5-minute time point
133 and persisted for up to 30 minutes (Fig. 4a). Ectopic expression of RNAi-resistant GFP-
134 Swip1 rescued β 1-integrin endocytosis in Swip1-silenced cells and increased the uptake in
135 control siRNA-transfected cells (Fig. 4b). Reduced integrin uptake was specifically due to
136 Swip1 silencing and not lower integrin levels, as evidenced by total β 1-integrin protein levels
137 remaining unaffected by Swip1 silencing, along with surface levels of total, active and
138 inactive β 1-integrins (Extended Data Fig. 4b-c). We then asked whether the Rab21-Swip1
139 complex could discriminate between active and inactive β 1-integrins. Internalization of
140 inactive β 1-integrin (Mab13 antibody) was unaffected by Swip1 or Rab21 silencing (Fig. 4c).
141 These data are in line with previous reports of active β 1-integrins signaling from Rab21
142 endosomes¹⁴ and Rab21-integrin interaction requiring the conserved KR-residues within the
143 integrin α -subunit cytoplasmic tail GFFKR-motif¹¹. Thus, this process potentially interferes
144 with conserved salt bridge interactions (between α -subunit R and the conserved acidic

145 residue of the β -cytoplasmic domain) known to stabilize integrins in their inactive
146 conformation²⁵.

147 To assess the impact of Rab21 in Swip1-mediated recruitment of integrins, we mutated the
148 key Rab21-interacting residues (KR1160/61AA) in the integrin $\alpha 2$ -subunit^{11,14}. This
149 significantly reduced integrin co-localization with Swip1-positive structures (Fig. 4d).
150 Furthermore, colocalization of $\beta 1$ -integrin with Swip1 was reduced in Rab21-silenced cells
151 (Fig. 4e); indicating that a preserved integrin-Rab21 interaction is required for Swip1-
152 mediated recruitment of the integrin receptor. In line with Rab21 interacting with multiple
153 integrin α -subunits¹¹, we found that Swip1 and Rab21 co-precipitated with several distinct
154 GFP-tagged integrin α -subunits (Fig. 4f). Importantly, Swip1 silencing decreased the
155 internalization of $\beta 1$ -integrin and several different α -subunits (Fig. 4g and Extended Data
156 Fig. 4d). Inhibition of receptor recycling with primaquine further amplified the difference in
157 integrin internalization between control- and Swip1-silenced cells (Fig. 4g and Extended Data
158 Fig. 4d). This indicates that Swip1 regulates integrin traffic at the step of internalization,
159 where it specifically regulates endocytosis of Rab21-bound active integrins.

160

161 **Swip1 regulates integrin uptake via the CG-pathway**

162 To explore the role of the CG-pathway in Swip1-mediated endocytosis, we silenced Arf1 and
163 IRSp53, both essential members of the CG-pathway, with two independent siRNAs. This
164 significantly decreased $\beta 1$ -integrin endocytosis in MDA-MB-231 cells (Extended Data Fig.
165 5a). Furthermore, integrin endocytosis was impaired in IRSp53-null mouse embryonic
166 fibroblasts (IRSp53^{-/-} MEF; Extended Data Fig. 5b). This was specifically due to reduced
167 integrin uptake and not due to lower integrin levels since total integrin levels were unaffected
168 by loss of IRSp53 (Extended Data Fig. 5b). Overexpression of ectopic GFP-Swip1
169 significantly increased integrin uptake (Extended Data Fig. 5c). This was dependent on the

170 CG-pathway machinery, as depletion of IRSp53 abolished GFP-Swip1 overexpression-
171 induced β 1-integrin endocytosis (Fig. 4h). The ability of ectopic Swip1 to augment β 1-
172 integrin endocytosis was most likely due to Swip1 overexpression-augmented recruitment of
173 β 1-integrins to IRSp53 (Fig. 4i, Extended Data Fig. 5d). Taken together, these data link
174 Swip1 with β 1-integrin endocytosis by the CG-pathway under basal conditions.

175

176 **Swip1 is a cargo adaptor for the CG-pathway**

177 CG-endocytosis is the major route for the bulk uptake/internalization of different kinds of
178 cargo⁵ whereas Rab21 has been primarily linked to integrin internalization¹¹. To explore the
179 possibility that β 1-integrins enter the CG-pathway, we imaged the uptake of plasma
180 membrane-labelled active β 1-integrin with 10 kDa dextran; a fluid phase cargo for the CG-
181 pathway. Immediately after endocytosis (2 and 5 minutes), integrins and dextran co-localized
182 as clearly as dextran labelled with two different dyes (Fig. 5a). Moreover, a large proportion
183 of active β 1-integrin (around 50%) colocalized with endocytosed dextran, while around 20%
184 colocalized with transferrin (Extended Data Fig. 5e), indicating that both CME- and CG-
185 pathways are active and facilitate uptake of active integrins. To assess whether Swip1 is a
186 cargo-adaptor or an integral member of the CG-pathway, we investigated if it regulates the
187 endocytosis of other CG-cargos. Swip1 silencing had no effect on the uptake of 10 kDa
188 dextran or MHCI (Fig. 5b-c). In contrast, silencing of IRSp53 significantly impaired
189 endocytosis of both cargoes, validating the approach. Similar data were obtained in two
190 additional triple negative breast cancer cell lines MDA-MB-468 and BT-20, where Swip1
191 silencing significantly reduced β 1-integrin uptake, but not MHCI uptake (Fig. 5d, Extended
192 Data Fig. 6a). The effect on β 1-integrin endocytosis was more prominent in the MDA-MB-
193 468 cells, which express higher endogenous Swip1 than the BT-20 cells (Extended Data Fig.
194 6b). Furthermore, Swip1 depletion did not affect the endocytosis of transferrin or EGFR
195 (Extended Data Fig. 6c-d), which are internalized through CME or dynamin-dependent non-

196 clathrin endocytosis^{26,27}. Thus, Swip1 regulates endocytosis of β 1-integrin, but not of other
197 CG cargos, indicative of a role for Swip1 as an integrin-specific CG-cargo adaptor.
198 The CG-pathway responds specifically to transient changes in cell membrane tension.
199 Constitutive activity of the pathway is augmented following a strain relaxation, such as
200 shifting cells from hypotonic to isotonic medium leading to a decrease in membrane
201 tension²⁸. Treatment of cells with hypotonic medium followed by a shift to isotonic medium,
202 significantly increased uptake of 10 kDa dextran and β 1-integrin, as compared to the cells in
203 isotonic medium. While dextran-uptake was elevated similarly in control- and Swip1-
204 silenced cells, when cells were shifted from hypotonic to isotonic medium, β 1-integrin uptake
205 did not increase by this treatment in the Swip1-silenced cells, in line with the notion of Swip1
206 facilitating specifically β 1-integrin uptake through the CG-pathway (Fig. 5e, Extended Data
207 Fig. 7a). This observation further confirmed β 1-integrin as a Swip1 recruited cargo for the
208 CG-pathway.

209

210 **Swip1 associates with Arf1 to direct integrin cargo towards CG-endocytosis**

211 To investigate the mechanism through which Swip1 provides cargo-specificity to the CG-
212 pathway, we silenced Rab21 and assessed the colocalization of the CG-pathway component
213 IRSp53. After Rab21 silencing, colocalization of IRSp53 with Swip1 was significantly
214 reduced, indicating that recruitment of Swip1 to the CG-pathway is dependent on binding to
215 Rab21 and β 1-integrin (Fig. 5f). Swip1 did not interact directly with IRSp53, while IRSp53
216 still associated with VASP, a known IRSp53 interactor²⁹⁻³¹ (Extended Data Fig. 7b-c). Next,
217 we explored the possible link between Swip1 and Arf1. Unexpectedly, we found that Swip1
218 associates preferentially and specifically with the inactive mutant (Arf1^{T31N}), but not the
219 active Arf1 (Arf1^{Q71L}; Fig. 5g). Arf1 localization at the plasma membrane precedes the
220 formation of CG endocytic tubules, and its activation is required for CG-endocytosis^{9,32}.

221 Since Swip1 is not activating the CG-pathway, nor an integral part of it, we propose a model
222 where Swip1 targets Rab21-bound integrins to the CG-pathway as a pre-assembled module
223 with inactive Arf1, which is then recruited to the endocytic CG-machinery.

224 Cumulatively, these data imply that Swip1 specifically directs integrin cargo towards CG-
225 endocytosis, rather than affecting the overall activity of this pathway. These data help to
226 explain the long-standing conundrum whereby active Rab21 is required for integrin
227 endocytosis, yet binds integrins in both GDP- and GTP-bound states¹¹. Here we show that
228 Swip1 interacts specifically with Rab21-GTP, coupling active Rab21 and integrin cargo to
229 CG-endocytosis.

230

231 **Integrin trafficking by the CG-pathway requires actin binding to Swip1**

232 A common emerging theme among non-clathrin endocytosis is a reliance on the actin
233 cytoskeleton³³. Intrigued by the established actin-binding activity of Swip1³⁴, we investigated
234 whether this function was important for Swip1-mediated integrin CG-endocytosis. Deleting
235 the first EF-hand domain (EF1) rendered Swip1 unable to bind actin, concordant with a
236 previous report³⁴, and abolished its ability to facilitate integrin endocytosis (Fig. 6a-c). In
237 contrast, EF2 deletion had no significant effect on Swip1-induced integrin uptake. This
238 indicates that Swip1 binding to actin is necessary for its ability to induce integrin
239 endocytosis. SIM imaging revealed F-actin overlap with Swip1 and β 1-integrin close to the
240 cell-ECM interface (Fig. 6d), indicating that Swip1 and the actin cytoskeleton are in close
241 proximity during integrin endocytosis.

242 In addition to Swip1 localization to cell-ECM-proximal structures, we observed
243 Swip1 deeper inside the cell, where it overlapped with Rab21-positive endosome-like
244 vesicles (Fig. 6e) and F-actin in discrete puncta around Rab21 vesicles (Fig. 6e yellow
245 arrows, Supplementary Video 3). Similar localization was visualized using GBP-APEX

246 (GFP-binding protein soybean ascorbate peroxidase) labelled GFP-Swip1 imaged with
247 electron microscopy (Fig. 6f)³⁵. Swip1 localized to filaments close to the plasma membrane
248 and in the vicinity of endosomes (Fig. 6e pink arrow and 6f blue arrows). Swip1 localization
249 with actin on Rab21 endosomes led us to investigate whether Swip1 regulates endosome
250 movement. Silencing of Swip1 significantly reduced the speed of GFP-Rab21 vesicles, but
251 not vesicle number (Extended Data Fig. 7d), and restricted their subcellular distribution to the
252 cell periphery (Fig. 6g, Supplementary Videos 4-5). The motility of Rab21 vesicles was
253 actin-dependent, as the actin inhibitor cytochalasin D reduced vesicle speed (Fig. 6h),
254 consistent with previous observations¹¹. Furthermore, re-expression of WT-Swip1, but not
255 the actin binding-deficient EF1-deleted-Swip1, fully restored vesicle speed (Fig. 6i, Extended
256 Data Fig. 8a). Taken together, these data highlight a role for actin in both Swip1/Rab21-
257 dependent integrin CG-endocytosis and Rab21-mediated integrin endosomal traffic within
258 the cell (Fig. 6j).

259

260 **Swip1 regulates adhesion turnover, migration and invasion**

261 Integrin endocytosis and intracellular transport are crucial for integrin turnover, cell
262 migration and invasion^{15,36}. Concordant with this notion we found that vinculin-containing
263 focal adhesions accumulated in Swip1-silenced cells on collagen-I-, fibronectin- and laminin-
264 coated surfaces (Fig. 7a). This phenotype was also present in cells silenced for Arf1 or
265 IRSp53 (Extended Data Fig. 8b), indicating that CG-endocytosis of integrins may regulate
266 adhesion dynamics and cell motility. Using live-cell imaging of paxillin-positive focal
267 adhesions, we observed significantly slower adhesion assembly and disassembly rates in
268 Swip1-silenced cells compared to control cells (Fig. 7b). Furthermore, live imaging of BiFC
269 Rab21-Swip1 complexes and paxillin revealed significant enrichment of BiFC signal in close
270 proximity to focal adhesions, indicating that, at the ventral surface of the cell, the Swip1-

271 Rab21 interaction occurs preferentially in the vicinity of adhesion sites (Fig. 7c,
272 Supplementary Video 6). Swip1 regulation of focal adhesions correlated with significantly
273 impaired cell migration (Fig. 7d, Extended Data Fig. 8c), in line with previously reported
274 migration defects of IRSp53-null fibroblasts³¹. Swip1 silencing also inhibited the migration
275 speed of randomly migrating MDA-MB-231 and MDA-MB-468 cells (Extended Data Fig. 9)
276 and MDA-MB-231 cell invasion through a 3D collagen matrix (Fig. 7e). These data indicate
277 that Swip1 supports integrin adhesion dynamics, in concert with the migration and invasion
278 of triple-negative breast cancer (TNBC) cells.

279

280 **High levels of Swip1 are a negative prognostic factor in triple-negative breast cancer**

281 To assess the clinical relevance of our findings, we analysed Swip1 expression in a cohort of
282 human breast cancer samples. Quantitative PCR (qPCR) analyses of Swip1 mRNA levels
283 from 192 breast cancer specimens revealed that Swip1 expression was significantly increased
284 in the highest-grade tumors and the most metastatic breast cancer subtypes: HER2-positive
285 (HER2+) and TNBC (Extended Data Fig. 10). These findings were further validated by
286 immunohistochemistry of Swip1 in HER2+ and TNBC tissue microarrays (Extended Data
287 Fig. 10b). Swip1 was highly expressed in a large proportion of both breast tumour subtypes
288 (65-75%). However, only in the case of TNBC was high Swip1 staining associated with a
289 poorer clinical outcome (Fig. 7f). Moreover, we found that patients with high membranaral
290 Swip1 expression had a more pronounced correlation with poor clinical outcome (Extended
291 Data Fig. 10c-d). Importantly, the Cox proportional hazards model showed that high
292 membranaral Swip1 is associated with a poorer prognosis, after adjustment for Ki67-positivity,
293 tumour size, lymph node metastasis or tumour grade (Extended Data Fig. 10d). Finally, we
294 observed that TNBC patients with high membranaral Swip1 had significantly more lymph node
295 metastasis compared to medium-low membranaral Swip1-expressing patients (Fisher's exact

296 test, $p=0.037$) (Extended Data Fig. 10e). These data demonstrate that elevated Swip1 levels
297 strongly and independently correlate with breast cancer metastasis and reduced survival in
298 TNBC. These findings support the use of Swip1 as a prognostic marker for TNBC and as a
299 potential drug target for this clinically challenging breast cancer subtype.

300

301

302 **Discussion**

303 Swip1 has not been previously associated with endocytosis and evidence for specific cargo
304 adaptors or selective uptake in the CG-endocytosis pathway has been lacking. Our findings
305 place Swip1 as a validated cargo-specific adaptor for the CG-pathway. Swip1 directs active
306 Rab21 and β 1-integrins to the CG-pathway and is necessary for active integrin endocytosis
307 through this route, while fully dispensable for the uptake of other CG-cargos. This
308 demonstrates an important and unexpected feature of this pathway: cargo-specific adaptor-
309 based recruitment of receptors. It also highlights the possibility of unprecedented cargo-
310 selective functions for the CG-pathway in a manner similar to that described for numerous
311 other endocytosed proteins following different endocytosis routes.

312 We find that IRSp53 is required for CG-pathway uptake of integrins and that this is important
313 for efficient cell migration and invasion. This adds a pathway to the list of IRSp53-regulated
314 cell migration and invasion mechanisms, including filopodia generation^{29,37}, membrane
315 ruffling³⁸ and curvature sensing with WAVE at the neck of membrane invaginations³⁹.

316 Moreover, our findings shed light on previous studies demonstrating that Arf1 depletion
317 results in defective adhesion and migration in MDA-MB-231 cells⁴⁰⁻⁴². Integrin traffic is a
318 key regulator of cell motility and adhesion dynamics in many different contexts⁴³⁻⁴⁵. We
319 show that Arf1-depletion significantly inhibits integrin uptake and induces accumulation of
320 large focal adhesions, similarly to Swip1 and IRSp53 silencing. These data link integrin
321 uptake via the CG-pathway to regulation of cell adhesion. It has been shown that Arf1 is

322 recruited to the forming endocytic pit long before scission, and that Arf1 activation is a key
323 regulatory step in promoting endocytosis via the CG-pathway^{9,23}. Our observation that Swip1
324 associates with inactive Arf1 supports a model where inactive Arf1 associates with the
325 Swip1-Rab21GTP-integrin complex and thereby concentrates the integrin cargo at the site of
326 the forming pit. Subsequently, activation of Arf1 releases the cargo from its adaptor for
327 association with actin, which persists during endocytosis through the CG-pathway.

328 Interestingly, knockout of *Swip-1* in *Drosophila* results in a mild adhesion defect similar to
329 deletion of the Rho-GAP-domain-containing protein GRAF1, another regulator of CLIC
330 formation, suggesting an *in vivo* relevant role for Swip1 in regulating cell-ECM
331 interactions^{32,46}. We find that Swip1 facilitates cancer cell migration *in vitro* and that high
332 Swip1 correlates with increased cancer dissemination in patients, in line with Swip1 driving
333 increased actin protrusion and migration in metastatic lung adenocarcinoma cells⁴⁷. In
334 macrophages, inflammatory shock-induced migration is Swip1-dependent^{48,49}, while Swip1
335 deletion in mice induces faster B-cell migration *in vivo*; suggesting cell type- and possibly
336 migration mode-specific roles for Swip1⁵⁰. Importantly, these studies focus on the role of
337 Swip1 as an actin regulator and the potential role of integrin traffic was not investigated.

338 Here, we show that Swip1 acts as a cargo-specific adaptor that bridges the CG endocytic
339 machinery to Rab21-bound integrins, and couples Rab21 endosomes and their motility in
340 cells, to the actin cytoskeleton. This dual functionality of Swip1 regulates cell adhesion
341 turnover, migration and invasion. Perhaps unsurprisingly, given the importance of these
342 events in cancer progression, Swip1 expression has clinically relevant implications for
343 TNBC. Thus, Swip1 and the mechanism of its interaction with Rab21 offer potentially
344 exciting therapeutic targets for metastatic breast cancer.

345

346 **Acknowledgments:**

347 The authors acknowledge Euro-BioImaging (www.eurobioimaging.eu) for providing access to
348 imaging technologies and services via the Finnish Advanced Light Microscopy Node (Turku,
349 Finland). We thank P. Laasola, J. Siivonen and Anja Gödicke for technical assistance, the Ivaska
350 lab for critical reading of the manuscript and H. Hamidi for editing of the manuscript. We thank
351 Virgilio Faila, Bernd Zobiak and Markku Saari for help with the microscopes and Dirk Mielenz,
352 Aymelt Itzen and Peter Jackson for providing reagents. The Cell Imaging and Cytometry core
353 (Turku Bioscience Centre, University of Turku and Åbo Akademi University and Biocenter
354 Finland), the Euro-BioImaging Finnish Node, the Electron Microscopy Unit and Histocore at the
355 University of Turku and the UMIF (UKE Microscopy Imaging Facility, Universitätsklinikum
356 Hamburg, Eppendorf) are acknowledged for services, instrumentation and expertise. This study
357 has been supported by DFG (VE 750/2-1) and Alexander von Humboldt-Foundation (S.V.),
358 ProExzellenzia Hamburg and Academy of Finland (321493 to P.M.L. 325464 to J.I.), an ERC
359 CoG grant 615258 (J.I.); by grants and a fellowship from the National Health and Medical
360 Research Council of Australia (grants APP1140064 and APP1150083 and fellowship
361 APP1156489 to R.G.P.) and the Australian Research Council Centre of Excellence in Convergent
362 Bio-Nano Science and Technology, CE140100036 (R.G.P.).

363

364 **Author contributions:**

365 Conceptualization, S.V. and J.I.; Methodology, P.M.L., N.Z.J., C.S., R.G., G.J., H.A., J.R.W.C.,
366 M.S., S.M., S.V., R.G.P., J.R. and J.I.; Formal Analysis, P.M.L., N.Z.J., C.S., R.G., G.J., P.K.,
367 R.E.K., L.O.F., H.Z., S.M., M.S., S.V. R.G.P., J.R. and J.I.; Investigation, S.V., P.M.L. and J.I.;
368 Resources, P.C., S.L., M.A., G.S. and A.D.; Writing – Original Draft, P.M.L. and J.I.; Writing –
369 Review and Editing, S.V., P.M.L., G.J., N.Z.J., J.R.W.C., R.G.P. and J.I.; Supervision, P.M.L.,
370 S.V. and J.I.; Funding Acquisition, S.V., M.A., P.M.L., R.G.P. and J.I.

371

372 **Competing interests:**

373 Authors declare no competing interests.

374

375 **Figure legends:**

376

377 **Fig. 1. Swip1 (EFHD2) interacts directly with active Rab21.**

378 **(a)** SILAC proteomics analysis of GFP-Trap pulldowns in MDA-MB-231 cells expressing GFP-CA-Rab21^{Q78L}
379 (constitutively active GTP-bound Rab21) vs GFP alone. Plot shows mean fold-changes from forward and
380 reverse experiments against absolute protein abundances (intensity-based absolute quantification, iBAQ).
381 Abundance bins were defined by including 1000 proteins in a subsequent order. Log₁₀ fold change of proteins
382 were tested for statistical significance using double-sided significance B tests. No multiple hypothesis correction
383 method was applied, due to the small number of selected proteins for the statistical analysis. Proteins with a *P*-
384 value < 0.01 are represented by a triangle, while non-significant proteins are shown as circles. *P*-values are
385 depicted in the figure for a selected set of proteins. Proteins in red are markedly enriched in the CA-Rab21
386 fraction and proteins in blue are known endosomal proteins clathrin (CLTA, CLTB, CLTC), AP2 (AP2A1,
387 AP2B1, AP2M1, AP2S1), caveolin (CAV1) and dynamin II (DNM2), which are not specifically enriched. **(b)**
388 Representative immunoblots of GFP-Trap pulldowns from MDA-MB-231 cells transfected with the indicated
389 constructs and probed for GFP and for endogenous Swip1. GFP-DN-Rab21: Rab21^{T33N} dominant negative,
390 GDP-bound/nucleotide-free (n = 3 independent experiments). **(c)** A Coomassie-stained gel and immunoblot of
391 GST pulldowns with the indicated GST-tagged proteins and recombinant Rab21 bound to a non-hydrolysable

392 form of GTP (GppNHP; active Rab21), GDP or no nucleotide after EDTA treatment (nuc free). Rab21-effector
393 GST-APPL1 is used as a positive control (n = 3 independent experiments).

394

395 **Fig. 2. Swip1 interacts with Rab21 and β 1-integrin.**

396 **(a)** Representative MDA-MB-231 cell expressing GFP-Rab21 and immunostained for Swip1. Arrows point to
397 regions of overlap between Swip1 and GFP-Rab21. Scale bar, 10 μ m. Micrograph is representative of 2
398 independent experiments. **(b)** Endogenous Rab21 and Swip1 are in close proximity in MDA-MB-231 cells. A
399 proximity ligation assay (PLA; green spots) with the indicated antibodies is quantified. Goat IgG was included
400 as a negative control and nuclei were stained with DAPI. Scale bars, 20 μ m (n = 3). Data are presented as mean
401 values \pm 95% CI. Statistical significance was assessed with two-sided Mann Whitney test. **** $P < 0.0001$.
402 Number of cells examined over 3 independent experiments: Rab21-IgG, 121 and Rab21-Swip1, 126. **(c)**
403 Representative TIRF microscopy of live MDA-MB-231 cells expressing the BiFC constructs V1-Rab21 and V2-
404 Swip1 or Venus alone as a control. Scale bars, 5 μ m (main images) and 2 μ m (insets). Representative pictures of
405 3 independent experiments are shown. **(d)** MDA-MB-231 cells expressing mScarlet-I-Swip1 and GFP-Rab21
406 imaged using SIM. Blue and yellow squares highlight the regions of interest (ROI) in x-y that are magnified in
407 x-z projections. Scale bars, 5 μ m (main image) and 1 μ m (insets). **(e)** SIM x-z projections of MDA-MB-231
408 cells expressing mScarlet-I-Swip1, GFP-Rab21 and immunostained for β 1-integrin were quantified for co-
409 localization with mScarlet-I-Swip1. Each dot represents the co-localization fraction in one cell. Number of cells
410 examined over 2 independent experiments: GFP-Rab21, 16 and β 1-integrin, 22. Scale bar, 0.5 μ m.

411

412 **Fig. 3. Swip1 interacts with members of the CG pathway.**

413 **(a)** Representative immunoblots of GFP-Trap pulldowns from HEK293 cells transfected as indicated and blotted
414 for GFP, endogenous IRSp53, Arf1 and β 1-integrin (n = 2 independent experiments). **(b)** Representative
415 immunoprecipitation with control mouse IgG or anti-IRSp53 antibodies from MDA-MB-231 cell lysate probed
416 for endogenous Swip1, IRSp53 and Arf1 (n=2 independent experiments). **(c)** PLA with indicated antibodies
417 alone (negative controls) and together to assess colocalization. Number of analyzed cells over 2 independent
418 experiments: 12G10 only, 12; IRSp53 only, 18; 12G10 + IRSp53; 28. Scale bars, 10 μ m. **(d)** SIM x-z
419 projections of MDA-MB-231 cells expressing mScarlet-I-Swip1 and GFP-IRSp53 or Arf1-GFP. Scale bars, 0.8
420 μ m. **(e)** MDA-MB-231 cells expressing mScarlet-I-Swip1 and immunostained for endocytic adaptor proteins or
421 transfected as indicated, imaged with SIM and quantified for co-localization with mScarlet-I-Swip1. Each dot
422 represents the co-localization fraction in one cell. Data are mean values \pm 95% CI. Statistical significance was
423 assessed with two-sided Mann Whitney tests. **** $P < 0.0001$, ns=not significant. Number of analyzed cells over
424 3 independent experiments: Rab21, 50; AP2, 50; caveolin, 50; clathrin, 55; GFP-Rab21, 63; GFP-dynamin2, 63;
425 GFP-IRSp53, 53 and Arf1-GFP, 62. **(f)** Representative immunoblots of BiCAP pulldowns from MDA-MB-231
426 cells transiently transfected as indicated and blotted for GFP/Venus, endogenous IRSp53, dynamin I/II and β 1-
427 integrin (n = 2 independent experiments). The GFP antibody recognizes both V1-Rab21 and V2-Swip1 (see also
428 Ext. Data Fig. 2b). **(g)** Representative TIRF microscopy BiFC images of live MDA-MB-231 cells expressing
429 V1-Rab21+V2-Swip1 and mcherry-IRSp53. Yellow arrows point to V1-Rab21+V2-Swip1 puncta that travel
430 towards mcherry-IRSp53 puncta and then disappear from the TIRF plane. Scale bar, 1 μ m. Representative
431 pictures of 2 independent experiments are shown.

432

433 **Fig. 4. Swip1 mediates endocytosis of active integrins via the CG pathway.**

434 **(a)** Representative micrographs of active β 1-integrin internalization in control- and Swip1-silenced MDA-MB-
435 231 cells and quantification at 5, 15 and 30 minutes. Representative immunoblot to validate Swip1 silencing.
436 Scale bars, 30 μ m. **(b)** Quantification of active β 1-integrin internalization at 15 min in control- or Swip1-
437 silenced MDA-MB-231 cells expressing GFP or GFP-Swip1. Representative immunoblots of cell lysates probed
438 as indicated. **(c)** Representative micrographs and quantification of inactive β 1-integrin internalization in control-
439 , Swip1- and Rab21-silenced MDA-MB-231 cells. Scale bar, 10 μ m. **(d)** SIM x-z projections of MDA-MB-231
440 cells expressing mScarlet-I-Swip1 and GFP-tagged α 2-integrin-WT or mutant α 2 integrin-AA (integrin
441 cytoplasmic sequence and mutated residues are depicted). Co-localization of GFP-tagged proteins with
442 mScarlet-I-Swip1 was quantified. Scale bars, 0.5 μ m. **(e)** SIM x-z projections of control (siCTRL) or Rab21-
443 silenced (siRab21) MDA-MB-231 cells expressing mScarlet-I-Swip1 and immunostained for β 1-integrin. Scale
444 bars, 0.5 μ m. Co-localization between mScarlet-I-Swip1 and β 1 integrin was quantified. **(f)** Representative
445 immunoblots of GFP-Trap pulldowns from MDA-MB-231 cells transfected and blotted as indicated. **(g)**
446 Quantification of cell surface biotinylated β 1-integrin or α 6-integrin internalization in Swip1-silenced MDA-

447 MB-231 cells after the indicated times in the presence or absence of 100 μ M primaquine. Bar charts show data
448 as mean values \pm SEM. Statistical significance was assessed using multiple comparison t-tests for paired data,
449 with post hoc Holm-Sidak method, $\alpha=5.000\%$. For β 1-integrin, $***P=0.00934$, $*P=0.02015$; for α 6-
450 integrin, $*P=0.02196$, $**P=0.04683$. $n=3$ biologically independent experiments. **(h)** Quantification of β 1-
451 integrin internalization in control- or IRSp53-silenced MDA-MB-231 cells expressing GFP or GFP-Swip1.
452 Representative immunoblots of cell lysates probed as indicated. **(i)** Representative micrographs and
453 quantification of PLA with the indicated antibodies in MDA-MB-231 cells expressing GFP or GFP-Swip1.
454 Scale bars, 10 μ m.
455 Immunoblots are representatives of 3 independent experiments and calnexin is included as a loading control. (a,
456 b, f, h). Scatter dot plots show data as mean values \pm 95% CI. Statistical significance was assessed with two-
457 sided Mann Whitney tests. (b) $*P=0.0275$, $**P=0.0260$; (h) $***P=0.0003$; (i) $***P=0.0001$; (a-e, h)
458 $****P<0.0001$, ns=not significant. Number of analyzed cells over 3 independent experiments are indicated in
459 the Statistics and Reproducibility section.

460

461 **Fig. 5. Swip1 is a cargo adaptor for the CG pathway.**

462 **(a)** Double uptake of fluorescently labelled 10 kDa dextran-TMR (tetramethylrhodamine) with either dextran-
463 FITC or Alexa Fluor 488-conjugated anti- β 1-integrin antibody (12G10) in MDA-MB-231 cells for the indicated
464 times. Scale bars, 10 μ m (main image) and 3 μ m (inset). **(b)** Representative micrographs and quantification of
465 dextran-TMR or anti- β 1-integrin antibody (12G10 conjugated to Alexa Fluor 488) internalization in control-,
466 Swip1- (siRNA#1 or #2) or IRSp53- (siRNA#1 or #2) silenced MDA-MB-231 at 15 min. Scale bars, 10 μ m. **(c)**
467 Representative micrographs and quantification of Major Histocompatibility Complex I (MHCI) internalization
468 in control-, Swip1- (siRNA#1) or IRSp53- (siRNA#1) silenced MDA-MB-231 at 15 min. Scale bars, 10 μ m. **(d)**
469 Quantification of β 1-integrin and MHCI internalization in control- or Swip1- (siRNA#1 or #2) silenced MDA-
470 MB-468 and BT-20 cells at 15 min. **(e)** Quantification of anti- β 1-integrin antibody (12G10 conjugated to Alexa
471 Fluor 488) and 10 kDa TMR-Dextran uptake in steady state or after recovery from hypotonic shock in control
472 and Swip1- (siRNA#1 or 2) silenced MDA-MB-231 cells. **(f)** SIM x-z projections of control (siCTRL) or
473 Rab21-silenced (siRab21) MDA-MB-231 cells expressing mScarlet-I-Swip1 and immunostained for IRSp53.
474 Colocalization between mScarlet-I-Swip1 and endogenous IRSp53 was quantified. Scale bars, 0.5 μ m. **(g)** Cell
475 lysates from HEK293T cells transfected with HA-ARF1^{T31N} (inactive) or HA-ARF1^{Q71L} (active) were incubated
476 with 2 μ M of recombinant purified GST or GST-Swip1. Inputs and *in vitro* pull downs (IVBs) were loaded on
477 SDS PAGE, analyzed by Ponceau staining to detect GST or GST-Swip1, and subjected to Western Blot analysis
478 with the indicated antibody. Representative of 3 independent experiments is shown.

479 In all plots, data are presented as mean values \pm 95% CI. Statistical significance was assessed with two-
480 sided Mann Whitney tests. *P* values calculated compared to siCTRL condition: (b) $***P=0.0001$, $**P=0.0004$;
481 (d) $*P=0.0137$, $**P=0.0007$, $***P=0.0006$; (a-e) $****P<0.0001$, ns=not significant. Number of analyzed cells
482 over 3 independent experiments are indicated in the Statistics and Reproducibility section.

483

484 **Fig. 6. Swip1-actin binding regulates integrin traffic.** **(a)** Swip1 domains. EF: EF-hand domain containing a
485 calcium-binding site (shown in gray). **(b)** Representative GFP-pulldowns of 2 independent experiments in
486 HEK293 cells expressing GFP, GFP-Swip1, or the truncated versions of Swip1 and blotted as indicated. **(c)**
487 Quantification of β 1-integrin uptake at 15 min in MDA-MB-231 cells expressing either GFP, GFP-Swip1 or the
488 truncated versions of Swip1. **(d)** SIM x-z projections of MDA-MB-231 cells expressing mScarlet-I-Swip1,
489 immunostained for β 1-integrin and labelled with phalloidin. Scale bar, 0.7 μ m. **(e)** Representative SIM x-y
490 image of MDA-MB-231 cells expressing mScarlet-I-Swip1 and GFP-Rab21 and labelled with phalloidin. White
491 squares highlight ROIs. ROI1 is magnified. Yellow arrows point to Swip1 overlap with actin on Rab21-
492 containing vesicles. Pink arrow indicates actin filaments in close proximity to the vesicle. Scale bars, 5 μ m
493 (main image) and 0.5 μ m (insets). **(f)** Electron microscopy images of GFP-Swip1 visualized using GBP-APEX.
494 Squares highlight ROIs, which are magnified. Arrows point to Swip1-APEX-positive patches adjacent to
495 filament-like actin structures (blue arrows) or vesicles (orange arrows). Scale bars, 0.5 μ m (top image), 0.2 μ m
496 (middle image), 0.2 μ m (inset 1) and 0.1 μ m (inset 2). **(g)** Average speed of Rab21 vesicles, per cell, close to the
497 TIRF plane over 2 min. Representative tracks of Rab21 vesicles in a control or a Swip1-silenced cell and
498 representative immunoblot validating Swip1 silencing are shown. Calnexin is included as a loading control.
499 Scale bar, 5 μ m. **(h)** Average speed of Rab21 vesicle movement per cell upon treatment with cytochalasin D. **(i)**
500 Average speed of Rab21 vesicle movement per cell upon Swip1 silencing and rescue with mScarlet-I-Swip1 or
501 mScarlet-I-AEF1. **(j)** Swip1 directs integrins to CG endocytosis.

502 Data in plots are presented as mean values \pm 95% CI. Statistical significance was assessed with two-
503 sided Mann Whitney tests: (c) $**P=0.0034$, $*P=0.0356$, (g) $**P=0.0005$, $***P=0.0003$, (h) $***P=0.0007$, (i)
504 $****P<0.0001$, (c, i) ns=not significant. Number of analyzed cells over 3 independent experiments: (c) GFP,

505 92; GFP-Swip1, 94; GFP-ΔEF1, 161 and GFP-ΔEF2, 101. (g) siCTRL, 31; siSwip1 siRNA #1, 33; siSwip1
506 siRNA #2, 39. (h) DMSO, 21 and Cytochalasin D, 18. (i) 33 cells per condition.

507

508 **Fig. 7. Swip1 regulates adhesion dynamics, cell motility and breast cancer progression.**

509 **(a)** Representative masks of vinculin-containing focal adhesions in control- or Swip1-silenced MDA-MB-231
510 cells on collagen I. Analysis of adhesion number and total adhesion area per cell on different ECM components.
511 Scale bars, 10 μm. **(b)** Visualization of GFP-paxillin dynamics in control- and Swip1-silenced cells. Color
512 scale represents focal adhesion localization over time. Assembly and disassembly rates are quantified. Scale bar,
513 10 μm. **(c)** Representative TIRF microscopy BiFC images of live MDA-MB-231 cells expressing V1-Rab21,
514 V2-Swip1 and mKate2-paxillin. Plot shows the nearest distance between EFHD2-Rab21 puncta or randomly
515 distributed puncta and paxillin-positive focal adhesion. Scale bars, 25 μm (main image) and 1 μm (inset). **(d)**
516 Migration of control-, Swip1- or Rab21-silenced MDA-MB-231 cells. Quantification of the wound area
517 coverage over time are shown. **(e)** Relative invasion through fibrillar collagen I of control- and Swip1-silenced
518 MDA-MB-231 cells. **(f)** Representative images of Swip1 staining in samples of HER2+ and TNBC breast
519 cancer tissue microarrays and quantification of the percentage of tumors with high, medium or low Swip1.
520 Overall survival of 133 TNBC patients with high (red) or medium and low (blue) staining of Swip1. Hazard
521 ratio (HR) was 1.84 (95% CI 1.05 to 3.23). Scale bars, 20 μm.

522 Box-plots display median and quartiles of the data. Mean is displayed as +. Whiskers display maxima
523 and minima. Representative immunoblots validating silencing are from 3 independent experiments; calnexin is a
524 loading control (a, b, d, e). Data are mean ± 95% CI (a) or mean ± SEM (b, d). Statistical significance was
525 assessed with two-sided Mann Whitney tests (a, b, c, e) or multiple comparison t-tests with post hoc Holm-
526 Sidak method (e). Number of analyzed cells over 3 independent experiments are indicated in Statistics and
527 Reproducibility section. *P* values calculated compared to siCTRL condition: (a-c) *****P*<0.0001, (a) Collagen
528 ****P*=0.0005, Fibronectin ****P*=0.0002 for Swip1 siRNA #1 and ****P*=0.0007 for siRNA #2, (d) siSwip1
529 siRNA #1, **P*=0.022118, 0.00148533, 0.00320197, 0.00598189, 0.00156902; siSwip1 siRNA #2,
530 ***P*=0.00161506, 8.929064e-005, 0.000190115, 0.000316543, 0.000100846; siRab21, **P*=0.0158582,
531 0.0101405, 0.00574356, 0.0240206, 0.0286109 for 8, 12, 16 and 18 hours, respectively; (e) **P*=0.0418,
532 ***P*=0.0055.

533

534

535

536 **References**

- 537 1. Kaksonen, M. & Roux, A. Mechanisms of clathrin-mediated endocytosis. *Nat. Rev.*
538 *Mol. Cell Biol.* **19**, 313–326 (2018).
- 539 2. Mettlen, M., Chen, P.-H., Srinivasan, S., Danuser, G. & Schmid, S. L. Regulation of
540 Clathrin-Mediated Endocytosis. *Annu. Rev. Biochem.* **87**, 871–896 (2018).
- 541 3. Sanger, A., Hirst, J., Davies, A. K. & Robinson, M. S. Adaptor protein complexes and
542 disease at a glance. *J. Cell Sci.* **132**, (2019).
- 543 4. Mayor, S., Parton, R. G. & Donaldson, J. G. Clathrin-independent pathways of
544 endocytosis. *Cold Spring Harb. Perspect. Biol.* **6**, (2014).
- 545 5. Maldonado-Báez, L., Williamson, C. & Donaldson, J. G. Clathrin-independent
546 endocytosis: a cargo-centric view. *Exp. Cell Res.* **319**, 2759–2769 (2013).
- 547 6. Ferreira, A. P. A. & Boucrot, E. Mechanisms of Carrier Formation during Clathrin-
548 Independent Endocytosis. *Trends Cell Biol.* **28**, 188–200 (2018).
- 549 7. Kirkham, M. *et al.* Ultrastructural identification of uncoated caveolin-independent
550 early endocytic vehicles. *J. Cell Biol.* **168**, 465–476 (2005).
- 551 8. Howes, M. T. *et al.* Clathrin-independent carriers form a high capacity endocytic
552 sorting system at the leading edge of migrating cells. *J. Cell Biol.* **190**, 675–691 (2010).
- 553 9. Sathe, M. *et al.* Small GTPases and BAR domain proteins regulate branched actin
554 polymerisation for clathrin and dynamin-independent endocytosis. *Nat. Commun.* **9**, 1835
555 (2018).
- 556 10. Thottacherry, J. J., Sathe, M., Prabhakara, C. & Mayor, S. Spoiled for Choice:
557 Diverse Endocytic Pathways Function at the Cell Surface. *Annu. Rev. Cell Dev. Biol.* **35**, 55–
558 84 (2019).
- 559 11. Pellinen, T. *et al.* Small GTPase Rab21 regulates cell adhesion and controls
560 endosomal traffic of beta1-integrins. *J. Cell Biol.* **173**, 767–780 (2006).
- 561 12. Pellinen, T. *et al.* Integrin trafficking regulated by Rab21 is necessary for cytokinesis.
562 *Dev. Cell* **15**, 371–385 (2008).
- 563 13. Högnäs, G. *et al.* Cytokinesis failure due to derailed integrin traffic induces
564 aneuploidy and oncogenic transformation in vitro and in vivo. *Oncogene* **31**, 3597–3606
565 (2012).
- 566 14. Alanko, J. *et al.* Integrin endosomal signalling suppresses anoikis. *Nat. Cell Biol.* **17**,
567 1412–1421 (2015).
- 568 15. Moreno-Layseca, P., Icha, J., Hamidi, H. & Ivaska, J. Integrin trafficking in cells and
569 tissues. *Nat. Cell Biol.* **21**, 122–132 (2019).

- 570 16. Meyer, K. & Selbach, M. Quantitative affinity purification mass spectrometry: a
571 versatile technology to study protein-protein interactions. *Front. Genet.* **6**, 237 (2015).
- 572 17. Hubner, N. C. *et al.* Quantitative proteomics combined with BAC TransgeneOmics
573 reveals in vivo protein interactions. *J. Cell Biol.* **189**, 739–754 (2010).
- 574 18. Jean, S. & Kiger, A. A. RAB21 Activity Assay Using GST-fused APPL1. *Bio-Protoc.*
575 **6**, (2016).
- 576 19. Zhu, G. *et al.* Structure of the APPL1 BAR-PH domain and characterization of its
577 interaction with Rab5. *EMBO J.* **26**, 3484–3493 (2007).
- 578 20. Del Olmo, T. *et al.* APEX2-mediated RAB proximity labeling identifies a role for
579 RAB21 in clathrin-independent cargo sorting. *EMBO Rep.* **20**, (2019).
- 580 21. Croucher, D. R. *et al.* Bimolecular complementation affinity purification (BiCAP)
581 reveals dimer-specific protein interactions for ERBB2 dimers. *Sci. Signal.* **9**, ra69 (2016).
- 582 22. Bhave, M. *et al.* Functional characterization of 67 endocytic accessory proteins using
583 multiparametric quantitative analysis of CCP dynamics. *Proc. Natl. Acad. Sci. U. S. A.* **117**,
584 31591–31602 (2020).
- 585 23. Kumari, S. & Mayor, S. ARF1 is directly involved in dynamin-independent
586 endocytosis. *Nat. Cell Biol.* **10**, 30–41 (2008).
- 587 24. Schnitzbauer, J., Strauss, M. T., Schlichthaerle, T., Schueder, F. & Jungmann, R.
588 Super-resolution microscopy with DNA-PAINT. *Nat. Protoc.* **12**, 1198–1228 (2017).
- 589 25. Park, E. J., Yuki, Y., Kiyono, H. & Shimaoka, M. Structural basis of blocking integrin
590 activation and deactivation for anti-inflammation. *J. Biomed. Sci.* **22**, 51 (2015).
- 591 26. Caldieri, G. *et al.* Reticulon 3-dependent ER-PM contact sites control EGFR
592 nonclathrin endocytosis. *Science* **356**, 617–624 (2017).
- 593 27. McMahon, H. T. & Boucrot, E. Molecular mechanism and physiological functions of
594 clathrin-mediated endocytosis. *Nat. Rev. Mol. Cell Biol.* **12**, 517–533 (2011).
- 595 28. Thottacherry, J. J. *et al.* Mechanochemical feedback control of dynamin independent
596 endocytosis modulates membrane tension in adherent cells. *Nat. Commun.* **9**, 4217 (2018).
- 597 29. Krugmann, S. *et al.* Cdc42 induces filopodia by promoting the formation of an
598 IRSp53:Mena complex. *Curr. Biol. CB* **11**, 1645–1655 (2001).
- 599 30. Vaggi, F. *et al.* The Eps8/IRSp53/VASP network differentially controls actin capping
600 and bundling in filopodia formation. *PLoS Comput. Biol.* **7**, e1002088 (2011).
- 601 31. Disanza, A. *et al.* CDC42 switches IRSp53 from inhibition of actin growth to
602 elongation by clustering of VASP. *EMBO J.* **32**, 2735–2750 (2013).
- 603 32. Lundmark, R. *et al.* The GTPase-activating protein GRAF1 regulates the CLIC/GEEC
604 endocytic pathway. *Curr. Biol. CB* **18**, 1802–1808 (2008).

- 605 33. Hemalatha, A. & Mayor, S. Recent advances in clathrin-independent endocytosis.
606 *F1000Research* **8**, (2019).
- 607 34. Park, K. R. *et al.* Structural implications of Ca²⁺-dependent actin-bundling function
608 of human EFhd2/Swiprosin-1. *Sci. Rep.* **6**, (2016).
- 609 35. Ariotti, N. *et al.* Modular Detection of GFP-Labeled Proteins for Rapid Screening by
610 Electron Microscopy in Cells and Organisms. *Dev. Cell* **35**, 513–525 (2015).
- 611 36. Paul, N. R., Jacquemet, G. & Caswell, P. T. Endocytic Trafficking of Integrins in Cell
612 Migration. *Curr. Biol. CB* **25**, R1092-1105 (2015).
- 613 37. Lim, K. B. *et al.* The Cdc42 effector IRSp53 generates filopodia by coupling
614 membrane protrusion with actin dynamics. *J. Biol. Chem.* **283**, 20454–20472 (2008).
- 615 38. Miki, H., Yamaguchi, H., Suetsugu, S. & Takenawa, T. IRSp53 is an essential
616 intermediate between Rac and WAVE in the regulation of membrane ruffling. *Nature* **408**,
617 732–735 (2000).
- 618 39. Pipathsouk, A. *et al.* WAVE complex self-organization templates lamellipodial
619 formation. *bioRxiv* 836585 (2019) doi:10.1101/836585.
- 620 40. Koronakis, V. *et al.* WAVE regulatory complex activation by cooperating GTPases
621 Arf and Rac1. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 14449–14454 (2011).
- 622 41. Schlienger, S., Ramirez, R. A. M. & Claing, A. ARF1 regulates adhesion of MDA-
623 MB-231 invasive breast cancer cells through formation of focal adhesions. *Cell. Signal.* **27**,
624 403–415 (2015).
- 625 42. Norman, J. C. *et al.* ARF1 mediates paxillin recruitment to focal adhesions and
626 potentiates Rho-stimulated stress fiber formation in intact and permeabilized Swiss 3T3
627 fibroblasts. *J. Cell Biol.* **143**, 1981–1995 (1998).
- 628 43. Shafaq-Zadah, M. *et al.* Persistent cell migration and adhesion rely on retrograde
629 transport of β (1) integrin. *Nat. Cell Biol.* **18**, 54–64 (2016).
- 630 44. Ezratty, E. J., Bertaux, C., Marcantonio, E. E. & Gundersen, G. G. Clathrin mediates
631 integrin endocytosis for focal adhesion disassembly in migrating cells. *J. Cell Biol.* **187**, 733–
632 747 (2009).
- 633 45. Sahgal, P. *et al.* GGA2 and RAB13 promote activity-dependent β 1-integrin recycling.
634 *J. Cell Sci.* **132**, jcs233387 (2019).
- 635 46. Hornbruch-Freitag, C., Griemert, B., Buttgereit, D. & Renkawitz-Pohl, R. Drosophila
636 Swiprosin-1/EFHD2 accumulates at the prefusion complex stage during Drosophila myoblast
637 fusion. *J. Cell Sci.* **124**, 3266–3278 (2011).
- 638 47. Fan, C.-C. *et al.* EFHD2 promotes epithelial-to-mesenchymal transition and correlates
639 with postsurgical recurrence of stage I lung adenocarcinoma. *Sci. Rep.* **7**, 14617 (2017).

- 640 48. Zhang, S. *et al.* Swiprosin-1 deficiency impairs macrophage immune response of
641 septic mice. *JCI Insight* **3**, (2018).
- 642 49. Tu, Y. *et al.* EFhd2/swiprosin-1 regulates LPS-induced macrophage recruitment via
643 enhancing actin polymerization and cell migration. *Int. Immunopharmacol.* **55**, 263–271
644 (2018).
- 645 50. Reimer, D. *et al.* B Cell Speed and B-FDC Contacts in Germinal Centers Determine
646 Plasma Cell Output via Swiprosin-1/EFhd2. *Cell Rep.* **32**, 108030 (2020).

647

648

649 **Methods**

650 Our research complies with all relevant ethical regulations; the use of the patient samples was
651 approved by the Auria Biobank steering committee, University of Turku and the hospital
652 district of South West Finland. Approval number AB19-4522.

653

654 Cell culture, cell transfection and ECM coatings

655 MDA-MB-231 and MDA-MB-468 (triple-negative human breast adenocarcinoma) cells were
656 grown in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10 % fetal calf
657 serum (FCS) and 1 % L-glutamine. BT-20 (triple-negative human breast adenocarcinoma)
658 cells were grown in Eagle's Minimum Essential Medium supplemented with 10 % FCS and 1
659 % L-glutamine. Cells were purchased from the American Type Culture Collection (ATCC)
660 and were routinely monitored for mycoplasma contamination (Catalogue numbers: MDA-
661 MB-231, HTB-26; MDA-MB-468, HTB-132 and BT-20, HTB-19). Mouse embryonic
662 fibroblasts (MEFs)³¹ were cultured in DMEM supplemented with 20% FCS, 1% L-glutamine
663 and 1 µg/ml puromycin. Human embryonic kidney 293 (HEK293, ATCC catalogue number
664 CRL-1573) cells were cultured in DMEM supplemented with 20% FCS and 1% L-glutamine.
665 No commonly misidentified cell lines were used for this study. MDA-MB-231 was
666 authenticated by the German Collection of Microorganisms and Cell Cultures GmbH, using
667 STR profiling and PCR assays to test the presence of mitochondrial DNA sequences from
668 rodent cells such as mouse, rat, Chinese and Syrian hamster. The other cell lines used in the
669 study were not authenticated. Plasmids of interest were transfected using Lipofectamine 3000
670 (Thermo Fisher Scientific) or jetPRIME® (Polyplus transfection) according to the
671 manufacturer's instructions. The expression of proteins of interest was suppressed using 27
672 nM siRNA and lipofectamine siRNA Max (ThermoFisher Scientific) according to
673 manufacturer's instructions. The siRNA used as control (siCTRL) was Allstars negative
674 control siRNA (Qiagen, Cat. No. 1027281). The siRNA oligonucleotides targeting
675 Swiprosin-1 (Swip1) were purchased from Sigma (siRNA #1 Cat. No. SASI_Hs01_00186848
676 and siRNA #2 Cat. No. SASI_Hs01_00186847). The siRNA oligonucleotides targeting Arf1
677 and IRSp53 were purchased from Qiagen (siARF1#1,Hs_BCAR1_5 FlexiTube siRNA, Cat.
678 No. SI02757734; siBCAR1#6, Hs_BCAR1_6 FlexiTube siRNA, Cat. No. SI02757741).

679 Coverslips were coated with either 10 µg/mL of fibronectin (FC010 Sigma), 12 µg/mL of
680 laminin-1 (L4544 Sigma) or 300 µg/mL of collagen I from rat-tail (08-115 Sigma).

681

682 Plasmids

683 Human Rab21 (aa 16-225) constructs were cloned into a Gateway destination vector pgLAP1
684 (Addgene plasmid # 19702) to express Rab21 with an N-terminal GFP followed by a TEV
685 cleavage site and an S-Tag in mammalian cells. As entry vector, we used pCR8/GW/Topo
686 (Thermo Fisher, USA), in which human Rab21 was cloned by TOPO cloning. The Rab21
687 mutants Q76L (active) and T33N (inactive) were introduced into the entry clone by site-
688 directed mutagenesis. Mouse full-length Swip1, Δ EF1-Swip1 (deletion in the EF1 domain, aa
689 96-166) and Δ EF2-Swip1 (deletion at the EF2 domain, aa 134-159) were a kind gift from Dr.
690 Dirk Mielenz (Division of Molecular Immunology, Nikolaus-Fiebiger-Centre, University of
691 Erlangen-Nuremberg, Germany). The corresponding coding sequences were subcloned into
692 the pEGFP-N1 backbone vector using the XhoI and EcoRI restriction sites. Full-length Swip1
693 was also subcloned by TOPO cloning into the Gateway vector pCR8/GW/Topo. Then, a LR
694 clonase II reaction was performed to shuttle full-length Swip1 into pGEX-4T1. mScarlet-I-
695 Swip1 was generated from the GFP-tagged construct by introducing the mScarlet-I sequence
696 using the AgeI and MfeI restriction sites. To generate mScarlet- Δ EF1-Swip1, the Δ EF1-
697 Swip1 fragment was PCR amplified from pEGFP- Δ EF1-Swip1 using the 5'-
698 agatctcgaGATGGCCACGGACGAGTTGGC-3' and 5'-
699 cggtggatcCATCTTGAACGTGGACTGCAGCTCCTTAAAGG-3' primers, which added N-
700 and C-terminal sites for the XhoI and BamHI restriction enzymes respectively. This fragment
701 was then ligated into the mScarlet-I-Swip1 vector backbone, after both were digested with
702 XhoI and BamHI. Arf1-HA and Arf1-GFP were obtained from Addgene (plasmids #79409
703 and #49578). IRSp53-mcherry and IRSp53-GFP were generated by the Genome Biology Unit
704 supported by HiLIFE and the Faculty of Medicine, University of Helsinki, and Biocenter
705 Finland. pDEST-V1-Rab21 was generated by shuttling the human Rab21 sequence
706 (pENTR201-hRab21, ORFeome Library; Genome Biology Unit supported by HiLIFE and the
707 Faculty of Medicine, University of Helsinki, and Biocenter Finland) into the destination
708 vector pDEST-V1-ORF (Addgene 73635). pDEST-Swip1-V2 was generated by performing a
709 clonase reaction between pCR8/GW/Topo-Swip1 and pDEST-ORF-V2 (Addgene 73638).
710 pEF.DEST51-mVenus was obtained from Addgene (plasmid #154899).

711

712 Antibodies

713 The antibodies used in this work are listed in Supplementary Table 2.

714

715 Generation of stable cell lines and SILAC-cell culture treatment

716 To generate stable GFP-Rab21 expressing mammalian cell lines, a FRT (Flp Recombination
717 Target)-entry site was first introduced into MDA-MB-231 breast cancer cells using the Flp-In
718 technology (Thermo Fisher, USA). Briefly, MDA-MB-231 cells were transfected with
719 pFRT/lacZeo2 and stable clones were isolated using Zeocin as the selection marker (200
720 µg/ml). The resulting MDA-MB-231-FRT cell line was then co-transfected with the
721 pgLAP1-Rab21 plasmid and pOG44 and stable clones were selected in 500 µg/ml
722 Hygromycin-containing medium and tested for GFP-Rab21 expression. Stable MDA-MB-
723 231-GFP-Rab21 cell lines were cultivated in heavy (Arg-10/Lys-8) or light SILAC-DMEM
724 medium plus Hygromycin (200 µg/ml) for 12 days to ensure at least 10 replication cycles for
725 efficient labelling. Hygromycin supplementation was omitted for the last two days before the
726 co-IP experiment.

727

728 Screening for Rab21 interaction partners by GFP pulldown

729 Each mass spectrometry experiment consisted of a mixture of a GFP-pulldown in active
730 GFP-Rab21 expressing MDA-MB-231 cells (WT or active Rab21 Q76L mutant) grown in
731 heavy medium and a GFP-pulldown in control cells (expressing GFP or inactive GFP-Rab21
732 T33N mutant) grown in light medium (forward experiment). In the reverse experiment, the
733 heavy and light media were exchanged (label swap experiment). Briefly, co-IP samples were
734 prepared as follows. Cells (two 15 cm dishes) were grown until 60-80% confluence, washed
735 with ice cold PBSM (PBS + 5 mM MgCl₂), harvested in PBSM, pooled and washed again.
736 Cell pellets were resuspended in 600 µl lysis buffer LB (50 mM Tris, pH 7.5, 5 mM MgCl₂,
737 150 mM KCl, 1.3% n-beta-octyl-D-glucopyranoside, 10 % Glycerol, protease and
738 phosphatase inhibitors and 500 µM GppNHp for GFP-active Rab21-expressing cells or 500
739 µM GDP for GFP-inactive Rab21-expressing cells) and lysed by douncing 40x in a tissue
740 grinder (dounce homogenizer) and incubating for 20 min on ice. The insoluble fraction was
741 removed by centrifugation at 18000x g and the supernatant was incubated with 20 µl GFP-
742 trap agarose beads (Chromotek) for 60 min at 4°C by overhead rotation. Beads were then
743 washed three times with 500 µl washing buffer WB (50 mM Tris, pH 7.5, 5 mM MgCl₂, 300
744 mM KCl, 10 % Glycerol), combining the heavy, GFP-active Rab21 IP with the light, GFP-
745 inactive Rab21 IP (forward experiment) during the second washing step. Proteins were eluted
746 from the beads in 100 µl of U/T buffer (6 M urea, + 2 M thiourea in 10 mM HEPES, pH 8.0)
747 for 15 min with shaking at 1400 rpm at room temperature. The eluted proteins were collected
748 and the process repeated a second time to maximize protein yield. Eluted proteins were
749 precipitated by adding 70 µl 2.5 M Na-Acetate, pH 5.0, 1 µl GlycoBlue (Thermo Fisher,

750 USA) and 1700 μ l ethanol to the pooled elution fractions (200 μ l) in a 2 ml tube. After an
751 overnight incubation at 4°C, the precipitation mixture was centrifuged for 50 min at 20000x g
752 and the resulting pellet dried for 15-20 min at 60-70°C.

753 For in-solution protein digestion we followed standard procedures⁵¹. Briefly, pellets were
754 solubilized in U/T buffer, reduced with DTT, alkylated with iodoacetamide and digested by
755 sequential addition of LysC (Wako) and Trypsin (Promega) overnight at room temperature.
756 Peptides were desalted and stored on STAGE tips until LC-MS/MS analysis. Samples were
757 analyzed using 240 min acetonitrile gradients on a 20 cm long 75 μ m ID reversed phase
758 column filled with 3 μ m C18 beads (Dr. Maisch) using a Proxeon HPLC system (Thermo
759 Fisher) coupled to the electrospray ion source of a Q Exactive Plus mass spectrometer
760 (Thermo Fisher). The mass spectrometer was operated in the data dependent mode with a full
761 scan (AGC target 3E6; R = 70,000) followed by up to ten MS2 scans (R = 17,500; maximal
762 injection time 60 ms) and a dynamic exclusion for 30 sec. Raw files were analyzed using
763 MaxQuant (version 1.5.2.8) using default parameters and searched against a Uniprot human
764 protein database (2014-10).

765 For visualization purposes, all the identified proteins from each experiment were plotted (Fig.
766 1a, Extended Data Fig. 1a-d), where each spot corresponds to one identified protein by mass
767 spectrometry. Each plot is representative of two independent experiments (forward and
768 reverse, x- and y-axis), where every experiment consists of two independent IPs. The mean
769 log2FCs from both experiments was plotted against absolute protein intensities (intensity-
770 based absolute quantification, or iBAQ) and significance B was calculated according to Cox
771 & Mann (2008)⁵². The error function was estimated using the erfc as is implemented in the
772 pracma package⁵³, R package version 2.2.9. Abundance bins were defined by including 100
773 proteins in a subsequent order.

774 The proteomics data have been deposited to the ProteomeXchange Consortium via the
775 PRIDE⁵⁴ partner repository with the dataset identifier PXD016478. The Log10 transformed
776 ratios of the proteins identified by mass spectrometry are also available from the
777 Supplementary Information (Supplementary Table 1).

778

779 Immunoprecipitations, BICAP and immunoblotting

780 MDA-MB-231 or HEK293 cells expressing GFP-tagged or split Venus-tagged (V1 or V2)
781 proteins (one 10 cm dish per condition) were washed with cold PBS, harvested in PBS and
782 pelleted. The cell pellet was resuspended in 200 μ l of IP-lysis buffer (40 mM Hepes-NaOH,

783 75 mM NaCl, 2 mM EDTA, 1% NP40, protease and phosphatase inhibitors) and incubated at
784 +4 °C for 30 min, followed by centrifugation (10,000x g for 10 min, +4 °C). 20 µl of the
785 supernatant was kept aside as the lysate control. The remainder of the supernatant was
786 incubated with GFP-Trap beads (ChromoTek; gtrak-20), which bind to both GFP and to
787 complemented Venus (V1+V2), for 1 h at 4 °C. Finally, immunoprecipitated complexes were
788 washed three times with wash-buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 % NP-40)
789 and denatured for 5 min at 95°C in reducing Laemmli buffer before SDS-PAGE analysis
790 under denaturing conditions (4–20% Mini-PROTEAN TGX Gels). The proteins were then
791 transferred to nitrocellulose membranes (Bio-Rad Laboratories) before blocking with
792 blocking buffer (Thermo, StartingBlock (PBS) blocking, #37538) and PBS (1:1 ratio). The
793 membranes were incubated with primary antibodies diluted in blocking buffer overnight at
794 4°C. Following this step, membranes were washed three times with TBST and incubated with
795 fluorophore-conjugated secondary antibodies (LI-COR) diluted (1:10,000) in blocking buffer
796 at room temperature for 1 hour. Membranes were scanned using an infrared imaging system
797 (Odyssey; LI-COR Biosciences).

798 Antibody immunoprecipitation of endogenous proteins were performed on MDA-MB-231
799 cell lysates (one 10 cm dish per condition). Cells were washed with PBS and harvested in 200
800 µl of IP-lysis buffer (see above). SureBeads Protein G Magnetic beads (Bio-Rad
801 Laboratories, #161-4023) were thoroughly resuspended in their solution, and 100 µl (1 mg at
802 10 mg/ml) were transferred to a 1.5 ml tube. The beads were then magnetized and the
803 supernatant discarded, after which the beads were washed three times with PBS-T (0.1%
804 Tween). 2 µg of antibody or isotype matching IgG control (Supplementary Table 2) was
805 added to the beads and kept at room temperature under rotation for 30 min, after which the
806 beads were magnetized, supernatant was discarded and beads were washed 3x with PBS-T.
807 Cell lysate was then added to the beads and allowed to rotate for 1 h at room temperature. 25
808 µl of total lysate was set aside for total lysate control. Beads were then magnetized,
809 supernatant discarded and beads were washed 3x with TBS-T, after which samples were
810 centrifuged for several seconds at 600 x g. Beads were then magnetized and residual buffer
811 was aspirated off, before addition of sample buffer, boiling (10 min at 95°C) and separation
812 using SDS-PAGE. Protein transfer and detection was performed as described above.

813

814 Protein purification

815 For producing recombinant GST-tagged proteins, (Rab21 16-225, Swip1, GGA3), pGEX-
816 4T1-Rab21 16-225, pGEX-4T1-Swip1 or pGEX6P1-GGA3-BL21 Rosetta transformed cells

817 were grown and induced with 250 μ M IPTG at OD 0.5-0.8 at 22°C in LB media overnight.
818 Cells were then lysed and resuspended in 20 mM Tris, pH 7.5; 5 mM MgCl₂, 300 mM NaCl,
819 3 mM DTT. The desired GST-tagged protein was purified from this suspension with a gravity
820 GST-column. In the case of GST-Rab21, elution of the protein was followed by thrombin-
821 cleavage and gel filtration in 20 mM Tris, pH 7.5, 5 mM MgCl₂, 50 mM NaCl, 3 mM DTT
822 buffer using a Superdex S75 16/60 column attached to a GST-column to bind cleaved GST.
823 Fractions containing the monomeric proteins were pooled, concentrated via ultrafiltration
824 (Amicon Ultra, 15 mL, 10,000 MWCO) and flash-frozen in liquid nitrogen for long-term
825 storage at -80°C.

826 For producing His-fusion proteins (IRSp53, VASP and ARF1), E. coli BL21 Rosetta (DE3)
827 cells picked from individual colonies were used to inoculate 200 mL of LB medium
828 (containing ampicillin at 50 μ g/mL) and were grown overnight at 37 °C. Between 10 and 100
829 mL of the overnight culture was diluted in 1 l of LB and was grown at 37 °C (240 rpm
830 shaking) until it reached approximately OD = 0.4–0.6. Then, IPTG (1 mM) was added and
831 after the induction cells were pelleted down at 4000 x g for 15 min at 4 °C and pellets were
832 used immediately or conserved at -80 °C after washing in PBS. Bacterial pellets were
833 resuspended in His-lysis buffer (50 mM Tris pH 8, 300 mM NaCl, 10 mM imidazole, 1mM
834 β -mercaptoethanol, protease inhibitor cocktail (Roche, Basel, Switzerland), 10% glycerol);
835 samples were sonicated 3 times for 30 s/each on ice and were pelleted down at 30,778 x g for
836 30 min at 4 °C using a JA 20 Beckman rotor or at 100,000 x g for 45 min at 4 °C using a 55.2
837 Ti Beckman rotor. A total of 600 μ L of NiNTA beads (Qiagen), previously washed 3 times
838 with His-lysis buffer, was added to the supernatant and samples were incubated 1–2 h at 4 °C
839 while rocking. Beads were then washed 2 times in 20 mM imidazole, 600 mM NaCl, 50 mM
840 Tris pH 8, 1 mM β -mercaptoethanol, 10% glycerol and one time in 40 mM imidazole, 300
841 mM NaCl, 50mM tris pH 8, 1 mM β -mercaptoethanol, 10% glycerol (5 min, 4 °C). Beads
842 were packed in Poly-Prep® Chromatography Columns (BioRad) and eluted with 200 mM
843 imidazole, 50 mM Tris pH 8, 200 mM NaCl, 1 mM β -mercaptoethanol, 10% glycerol (500 μ l
844 fractions). Fractions, evaluated by Bradford assay and SDS-PAGE, were pooled together and
845 dialyzed. Samples were aliquoted, flash frozen and stored at -80 °C in 50 mM Tris pH 7.5,
846 200 mM NaCl, 1 mM DTT, 10% glycerol.

847

848 Nucleotide loading and GST pulldowns

849 To load Rab21 with either GppNHp or GDP, 200 μ M of recombinant Rab21 or GST-Rab21
850 were incubated with 10 mM EDTA and a 25x excess of nucleotide (5 mM GppNHp or GDP)

851 in exchange buffer (20 mM Tris pH 7.5, 2.5 mM MgCl₂, 50 mM NaCl and 3 mM DTT) for 1
852 h at 25 °C. The EDTA-based exchange reaction was then stopped by the addition of 40 mM
853 MgCl₂ and incubation for 15 min on ice. The buffer was then exchanged with measuring
854 buffer (20 mM Tris, pH 7.5, 5 mM MgCl₂, 50 mM NaCl and 3 mM DTT) to reach the
855 desired protein concentration using 10 kDa ultrafiltration devices (Amicon). Equal amounts
856 of nucleotide compared to the protein amount was added to ensure complete loading of
857 Rab21 with the desired nucleotide.

858 GST pulldowns using purified GST fusion proteins and recombinant Rab21 bound to a non-
859 hydrolysable form of GTP (GppNHp), GDP or no nucleotide (in the presence of EDTA) were
860 performed as follows. 50 µg of GST-Swip1 or GST-App11 was incubated with 200 µg of
861 recombinant Rab21 for 30 min before incubation with Glutathione Sepharose beads for an
862 additional 30 min. The proteins bound to the beads were divided in two fractions and
863 separated by SDS-PAGE electrophoresis, followed by either Coomassie staining or
864 immunoblotting with anti-Rab21 antibody. Pulldowns were performed three times.

865

866 Overlay assay

867 Nitrocellulose membranes were incubated in TBST 0.1% Triton X- 100 buffer and let do dry.
868 Equal or increasing amounts of recombinant-purified proteins were spotted on membranes
869 and let dry. Membranes, previously blocked in TBST 0.1% Triton X-100 5% Milk, were then
870 incubated with the recombinant protein of interest, resuspended in TBST 0.1% Triton X-100
871 5% Milk, 1–2 h at 4 °C. After extensive washing in TBST 0.1% Triton X-100, membranes
872 were subjected to western blot analysis with the desired antibodies.

873

874 *In vitro* binding GST-Swip1/Arf1 T31N/Q71L

875 Cell lysates from HEL293T cells transfected with HA-tagged ARF1 T31N or ARF1Q71L
876 (lysis buffer: 50 mM Tris HCl pH 7.4, 150 mM NaCl, 10 mM MgCl₂, 1% Triton X-100, 1
877 mM DTT, protease inhibitor cocktail) were incubated with equal amounts (2 µM) of GST-
878 Swip1 or GST as control for 1 h at 4 °C. Reactions were washed three times in lysis buffer.
879 After washing, beads were resuspended in 1:1 volume of 2x SDS-PAGE Sample Buffer,
880 boiled for 10 min at 95 °C, centrifuged for 1 min and then loaded onto polyacrylamide gels.

881

882 SIM microscopy and co-localization analysis

883 Cells growing on uncoated glass or collagen-1-coated dishes were fixed with 2%
884 formaldehyde, permeabilized with 0.3 % Triton X-100, blocked with 10 % horse serum and
885 incubated with antibodies against the indicated endogenous proteins. This was followed by
886 incubation with fluorophore-labelled secondary antibodies (Alexa-568, Alexa-488 or Alexa-
887 647 anti-mouse or anti-rabbit, Life Technologies). For visualization of Swip1-containing
888 invaginations, cells expressing mScarlet-I-Swip1 were incubated at 4°C for 30 min before
889 fixation. Cells were imaged with an OMX DeltaVision and spots co-localization analysis was
890 performed in Z stacks of the cells using the plugin ComDet in ImageJ
891 ([https://imagej.net/Spots_colocalization_\(ComDet\)](https://imagej.net/Spots_colocalization_(ComDet))), which allowed for a better detection of
892 the invaginations since it ignores inhomogeneous cytoplasmic background. Using this plugin,
893 we pinpointed the mScarlet-I-Swip1 spots (pixel size above 5), and analyzed co-localization,
894 based on proximity (pixel distance 4), with spots from the second channel stained for the
895 protein of interest. Then, the ratio of co-localization with mScarlet-I-Swip1 was calculated as
896 a percentage of co-localized spots per cell. At least 30 cells per condition were imaged and
897 analyzed. Co-localization plots show mean \pm 95 % CI. Statistical significance was calculated
898 compared to the control condition. Representative rendered images of the invaginations (x-z
899 plane) were visualized with IMARIS software (Oxford Instruments, version 8.1.2).

900

901 Proximity Ligation Assay (PLA)

902 MDA-MB-231 cells growing on coverslips were fixed, washed twice with PBS and
903 permeabilized with 0.3% Triton-X-100 in PBS for 15 min at room temperature. Cells were
904 stained using anti-Swip1 (1:100) and anti-Rab21 (1:50) primary antibodies diluted in 5%
905 horse serum for 1 h at room temperature. Proximity ligation was performed according to the
906 manufacturer's instructions (Duolink in situ PLA, Sigma-Aldrich). Interaction between
907 Swip1 and Rab21 in cells was detected using confocal microscopy (Leica TCS SP5, 63x/1.4
908 Apo oil objective) and the number of PLA spots per 1000 μm^3 was quantified using IMARIS
909 software. For the PLA between active β 1-integrin (12G10) and IRSp53, MDA-MB-231 cells
910 growing on glass-bottom dishes (and for Fig. 4i, expressing GFP or GFP-Swip1) were
911 incubated at 4 °C for 30 min before fixation, after which they were washed and permeabilized
912 as indicated above. Cells were stained using 12G10 (1:100) and anti-IRSp53 (1:300) primary
913 antibodies diluted in 5% horse serum for 1 h at room temperature. PLA was performed as
914 indicated above and imaged using a 3i (Intelligent Imaging Innovations, 3i Inc) Marianas
915 Spinning disk confocal microscope with a Yokogawa CSU-W1 scanner and a back

916 illuminated 10 MHz EMCDD camera (Photometrics Evolve) with a 63x/1.4 oil objective,
917 controlled by the Slidebook (version 6) software.

918

919 BiFC and TIRF microscopy

920 MDA-MB-231 cells growing in glass-bottom dishes were co-transfected with split Venus
921 constructs (pDEST-V1-Rab21 and pDEST-Swip1-V2) and imaged 30 h after transfection.
922 Imaging was performed using a DeltaVision OMX v4 (GE Healthcare Life Sciences) fitted
923 with an Olympus APO N 60x Oil TIRF objective lens, 1.49 NA used in TIRF illumination
924 mode. Emitted light was collected on a front illuminated pco.edge sCMOS (pixel size 6.5
925 mm, readout speed 95 MHz; PCO AG) controlled by SoftWorx. The TIRF angle for all
926 channels was maintained at 83.5°. Images were taken every 500 ms for 2 min, at 37 °C in
927 presence of 5 % CO₂. Imaging of the above-mentioned BiFC constructs together with
928 different endocytic vesicle markers was performed with a 3i (Intelligent Imaging Innovations,
929 3i Inc) Marianas Spinning disk confocal microscope with a Yokogawa CSU-W1 scanner
930 and a back illuminated 10 MHz EMCDD camera (Photometrics Evolve) using 63x/1.4 oil
931 objective. Cells were fixed with 2% formaldehyde, permeabilized with 0.3 % Triton X-100,
932 blocked with 10 % horse serum and incubated with antibodies against the indicated
933 endogenous proteins. This was followed by incubation with fluorophore-labelled secondary
934 antibodies (Alexa-568, Alexa-488 or Alexa-647 anti-mouse, anti-rabbit or anti-goat, Life
935 Technologies).

936

937 DNA Paint

938 For two-color single molecule localization microscopy (SMLM) (Extended Data Fig. 4a), we
939 used DNA-PAINT²⁴. Cells over-expressing Swip1-GFP and ARF1-HA were fixed and
940 labeled using primary antibodies against GFP (Abcam ab1218) and HA-tag (Cell Signaling
941 3724), respectively. Cells were then stained with appropriate secondary antibodies coupled to
942 PAINT DNA handles (Ultivue). Imaging was performed using a DeltaVision OMX v4 (GE
943 Healthcare Life Sciences) fitted with an Olympus APO N 60x Oil TIRF objective lens, 1.49
944 NA used in TIRF illumination mode. Emitted light was collected on a front illuminated
945 pco.edge sCMOS (pixel size 6.5 mm, readout speed 95 MHz; PCO AG) controlled by
946 SoftWorx. First, a TIRF image of Swip1-GFP was acquired, followed by the DNA-paint
947 acquisitions.

948 DNA paint imaging was done sequentially first for Swip1-GFP (10 000 frames, 50 ms) and
949 for ARF1 (10 000 frames, 100 ms) in PAINT buffer (10 mM Tris-HCl, 100 mM NaCl, 0.05

950 % Tween-20, pH 7.5) supplemented with 0.5 nM of the corresponding PAINT imager strands
951 coupled to AlexaFluor 647 (Swip1-GFP) or to AlexaFluor 568 (ARF1). For both conditions,
952 full laser power was used and the beam concentrator enabled. No cross-talk between the
953 channels was observed. The ThunderSTORM⁵⁵ ImageJ plugin⁵⁶, with the Phasor-based
954 localization 2D method⁵⁷, was used for the localization of single fluorophores. After filtering
955 out localizations to reject too low photon counts, translational shifts were corrected by
956 autocorrelation. Image reconstructions were performed using the ThunderSTORM ImageJ
957 plugin.

958

959 Uptake/endocytosis assays

960 MDA-MB-231, MDA-MB-468 and BT-20 cells were grown on uncoated plastic dishes or
961 glass coverslips unless stated otherwise. For integrin endocytosis assays, surface integrins
962 were labelled with an antibody that recognizes the active conformation of β 1-integrins
963 (12G10) at 4 °C followed by incubation at 37 °C for 15 min unless stated otherwise. The
964 antibody still left on the surface was washed away with acid (0.2 M Acetic acid, 0.5 M NaCl
965 pH 2.5). The cells were subsequently fixed with 2% formaldehyde, permeabilized with 0.05%
966 saponin and incubated with a fluorescent secondary antibody to visualize and quantify the
967 amount of internalized integrins. Several fields were randomly imaged with identical
968 microscope settings using a 3i (Intelligent Imaging Innovations, 3i Inc) Marianas Spinning
969 disk confocal microscope with a Yokogawa CSU-W1 scanner and a back illuminated 10
970 MHz EMCDD camera (Photometrics Evolve) using 63x/1.4 oil objective. Quantification of
971 endocytosed integrins was performed on 3D-projections of the cells using IMARIS software
972 with the spots detection function. The intensity sum of all the vesicles per cell was divided by
973 the volume of that cell. All the intensity values were then normalized to the average of all the
974 cells in the control condition (siCTRL). A similar procedure was followed for the uptake of
975 MHCI (SAB4700637 Sigma) and 9EG7 (active β 1-integrin).

976 For AlexaFluor 568-labelled transferrin (Transferrin-AF568, Thermo Fisher T23365) and 10
977 kDa dextran uptake experiments, MDA-MB-231 cells were treated with 1 mg/mL of
978 transferrin, 10 kDa dextran-TMR (D1816, Invitrogen) or 10 kDa amino dextran (Molecular
979 Probes) conjugated to FITC during the 15 min incubation at 37°C. In the case of the double
980 uptake experiments, cells were previously labelled with 12G10-AF488 antibody (Abcam,
981 ab202641) at 4 °C as described above. After the internalization step at at 37°C, the remaining
982 fluorescently labelled molecules at the cell surface were removed with an acid wash,

983 followed by fixation, labelling of plasma membrane with WGA lectin and imaging as
984 described above.

985 Surface biotinylation-based integrin trafficking assays were performed based on previously
986 published methods^{58,59} with some modifications. ELISA plates were prepared by coating
987 Nunc MaxiSorb 96-well plates (#44-2404-21, Thermo Fischer) with 50 µl/well 5 µg/ml anti-
988 integrin antibody in TBS o/n at +4 °C (see table for antibody details). Wells were blocked
989 with 5% BSA in TBS for 2 h +37 °C. MDA-MB-231, silenced three days prior to the
990 experiment as described above, were grown in 10% FCS-containing medium on 6 cm dishes
991 to 80% confluence. The cells were placed on ice and washed once with cold PBS. Cell
992 surface proteins were labelled with 0.13 mg/mL of EZ-link cleavable sulfo-NHS-SS-biotin
993 (#21331; Thermo Scientific) in serum-free DMEM for 30 min at +4 °C. Unbound biotin was
994 washed away with cold medium, and cells were incubated 15 min on ice in cold serum free
995 DMEM with or without 100 µM primaquine (#160393 Sigma; PQ). Pre-warmed serum-free
996 DMEM (with or without PQ) was added to cells. The biotin-labelled surface proteins were
997 allowed to internalize at +37 °C for the indicated time points, after which the cells were
998 placed quickly back on ice and rinsed with cold DMEM and with cold cell surface reduction
999 buffer (50 mM Tris-HCl, pH 8.6, 100 mM NaCl). The remaining biotin at the cell surface
1000 after internalization was removed with 30 mg/ml MesNa (63705; sodium 2-
1001 mercaptoethanesulfonate: Fluka) in MesNa buffer for 20 min at 4 °C, followed by quenching
1002 with 100 mM iodoacetamide (Sigma) for 15 min on ice. To detect the total amount of surface
1003 biotinylation, one of the cell dishes was left on ice after biotin labelling followed by treatment
1004 without reducing MesNa. For the 0 min internalization, cells were maintained on ice in
1005 serum-free DMEM until cell surface reduction with MesNA. The cells were lysed by
1006 scraping in lysis buffer (1.5% octylglucoside, 1% NP-40, 0.5% BSA, 1 mM EDTA protease
1007 and phosphatase inhibitors) and incubation at +4 °C for 20 min. Cell extracts were cleared by
1008 centrifugation (16 000 × g, 10 min, 4 °C). To determine the amount of internalized,
1009 biotinylated integrins, 50 µl of cell lysates were incubated in duplicate wells o/n +4 °C,
1010 washed extensively with TBS-T, incubated 2 h +4 °C with 1:1000 HRP-coupled streptavidin
1011 (#21130 Fisher) washed and detected with antibody for ELISA detection.

1012 For the FACS-based EGFR endocytosis assay, adherent cells were labeled with 1:500
1013 extracellular domain-binding EGFR antibody (#05-101, UpState) on ice for 30 min. Unbound
1014 antibody was washed away, and the cells were chased in warm medium in the presence or
1015 absence of 10 ng/ml EGF. Cells were washed with cold PBS and carefully collected by
1016 scraping. Cells were fixed for 10 min at 4 °C with 4% PFA, washed, and suspended in PBS

1017 followed anti-mouse AlexaFluor 647 secondary antibody (dilution 1:300 in PBS; from
1018 Invitrogen), washed with PBS and analysed with LSRFortessa (BD Biosciences). Data
1019 analysis was performed with Flowing software version 2 (Cell Imaging Core of the Turku
1020 Bioscience Centre). The geometric mean of the fluorescence intensity from cells labelled
1021 with secondary antibody alone was used as background and subtracted from the stained
1022 samples. For normalization, the background-corrected values were divided by the sum of all
1023 signals within one independent experiment. Representative raw flow cytometry data can be
1024 found in Supplementary Figure 1.

1025

1026 Hypotonic-isotonic shocks

1027 MDA-MB-231 cells were transfected with either siCTRL, siRNA #1 or siRNA #2 against
1028 Swip1 and used 96 hours after silencing. Cells were kept in either isotonic (100% incomplete
1029 DMEM) or hypotonic media (50% incomplete DMEM, 50% sterile double distilled water)
1030 for 1 min, followed by pulse of various cargos in isotonic media for 1 min. Pulse contained
1031 the following cargos: anti- β 1-integrin antibody (12G10 conjugated to AlexaFluor 488, 2
1032 μ g/ml), 1 mg/ml 10 kDa dextran conjugated to tetra methyl rhodamine and 10 μ g/ml
1033 transferrin conjugated to AlexaFluor 647. After the pulse, surface-bound cargoes were
1034 stripped with 0.2 M Acetic acid, 0.5 M NaCl pH 2.5 for 3 min on ice and then fixed with 2%
1035 PFA. Then, cells were imaged with confocal microscopy as described above and the cell
1036 mean intensity of each cargo was quantified using manual segmentation with ImageJ.

1037

1038 Electron microscopy and Apex labelling

1039 Apex labeling of GFP-Swip1 for electron microscopy was performed as previously described
1040 ³⁵. Briefly, MEFs were transfected with GFP-Swip1 and GBP-Apex (Addgene plasmid
1041 #67651) constructs using a Neon transfection system (as per manufacturer's instructions) and
1042 plated into 35 mm tissue culture dishes. 24 h post-transfection, cells were incubated on ice for
1043 30 min, then fixed in 2.5 % glutaraldehyde, washed 3x in cacodylate buffer and once in 1
1044 mg/ml 3,3'-diaminobenzidine (DAB; Sigma-Aldrich) solution in cacodylate for 5 min. Cells
1045 were then subjected to the DAB reaction in the presence of H₂O₂ for 30 min and, stained with
1046 1 % osmium tetroxide for 2 min. The cells were processed in situ with serial dehydration in
1047 increasing percentages of ethanol, then serial infiltration with LX112 resin in a Pelco
1048 Biowave microwave before polymerizing overnight at 60 °C. Ultra-thin (60 nm) sections

1049 were cut on a Leica UC6 microtome parallel to the culture dish and micrographs acquired
1050 using a Jeol 1011 transmission electron microscope.

1051

1052 Vesicle tracking

1053 For Rab21 vesicle tracking, MDA-MB-231 cells stably expressing GFP-Rab21 were
1054 transfected with one of two different siRNA sequences to deplete the levels of Swip1. In the
1055 rescue experiment (Fig. 6i), control- and Swip1-silenced cells were transfected with GFP-
1056 Rab21 and either mScarlet-I-Swip1 or mScarlet-I- Δ EF1-Swip1. The movement of the Rab21
1057 vesicles was followed for 2 min using TIRF microscopy (Visitron SD-TIRF Nikon Eclipse
1058 TiE with a 60x Olympus TIRF oil objective, NA: 1.49 or DeltaVision OMX v4 as described
1059 in the BiFC and TIRF microscopy section). GFP-Rab21 vesicles were imaged for 2 minutes
1060 in each cell, every 500 milliseconds. The TIRF angle was kept constant at 85.5°. The vesicles
1061 were detected and tracked using the spots tracking function in IMARIS software. The
1062 parameters used in the algorithm were an estimated diameter of spots/vesicles of 0.5 μ m,
1063 background subtraction and Brownian motion for modelling the vesicle movement, with a
1064 maximum distance of 20 μ m for displacement length and a maximum gap size of 3 μ m
1065 between spots. We used the mean speed of all vesicle tracks in one cell to then calculate the
1066 average speed of vesicles per cell. At least 10 cells per condition were analyzed and data
1067 from 3 independent experiments was quantified.

1068

1069 Focal adhesion analysis

1070 Cells were plated on dishes coated with the indicated extracellular matrix component
1071 (collagen I, laminin-1 or fibronectin), fixed and immunostained with an antibody that
1072 recognizes the focal adhesion component vinculin, present in mature adhesions. At least 6
1073 cells per condition per experiment were imaged and analyzed (18 cells per condition in total
1074 from 3 independent experiments). Vinculin-positive focal adhesions were detected from an
1075 image mask created using the ImageJ software following background subtraction and setting
1076 of median Gaussian filter (3.0). The number of focal adhesions (detected particles) and the
1077 total cell area occupied by focal adhesions per cell was quantified from the image mask.

1078

1079 Adhesion dynamics

1080 For adhesion dynamics studies, MDA-MB-231 cells transiently expressing GFP-paxillin were
1081 transfected with one of two different siRNA sequences to deplete the levels of Swip1. GFP-

1082 paxillin was imaged for 120 min at the TIRF plane with a Deltavision OMX using a 63x
1083 objective. Cells were imaged every 1 min, at 37 °C in presence of 5 % CO₂, using
1084 multiposition capabilities. Focal adhesion dynamics were then analyzed using the Focal
1085 Adhesion Analysis Server⁶⁰. Only focal adhesions with a lifetime minimum of 10 frames
1086 were analyzed, and the focal adhesions that were assembled and disassembled during the
1087 course of imaging were used for measuring focal adhesion kinetics.

1088

1089 Focal adhesion proximity analysis

1090 MDA-MB-231 cells expressing V1-Rab21, V2-Swip1 and mKate2-paxillin were imaged live
1091 using a TIRF microscope. Post-acquisition, images were denoised using Noise2Void⁶¹
1092 trained using the ZeroCostDL4Mic platform (v 1.11.1; ⁶²).

1093 To denoise the Swip1-Rab21 movies, individual Noise2Void models were generated for each
1094 movie using 300 epochs, 12288 image patches, a batch size of 128, and a starting learning
1095 rate of 0.0004. To denoise the mKate2-paxillin images, a single Noise2Void model was
1096 generated using 300 epochs, 56064 image patches, a batch size of 128, and a starting learning
1097 rate of 0.0004. Post-denoising, individual focal adhesions were automatically segmented
1098 using the focal adhesion server⁶⁰ while individual Swip1-Rab21 puncta were semi-
1099 automatically segmented using the Trainable Weka Segmentation tool implemented in Fiji⁶³.
1100 The nearest distance between Swip1-Rab21 puncta and paxillin-positive focal adhesion was
1101 measured using the Distance Analysis (DiAna) Fiji plugin⁶⁴. Images containing randomly
1102 distributed puncta within the cells (to assess their distance to focal adhesion) were generated
1103 using a custom Fiji macro (available as a Zenodo package as described below)⁶⁵.

1104

1105 Random cell migration

1106 Cells were seeded in 24-well plates (Greiner Bio-One) one day before imaging. The media
1107 was supplemented with 500 nM SiR-DNA (Cytoskeleton Inc) 2 h before imaging. Cells were
1108 then imaged live (37 °C, 5% CO₂) using a Nikon Eclipse Ti2-E microscope (Nikon) equipped
1109 with a sCMOS Orca Flash4.0 camera (Hamamatsu) and controlled by the NIS-Elements
1110 software (Nikon, v 5.11.01). Cells were imaged using a 20x Nikon CFI Plan Apo Lambda
1111 objective (NA 0.75) one frame every 10 minutes for 16 h. Cell nuclei were automatically
1112 segmented over time using the deep learning algorithm StarDist implemented in the
1113 ZeroCostDL4Mic platform and tracked using TrackMate_{62,66-68}. In particular, a custom

1114 StarDist model was generated using the ZeroCostDL4Mic platform ⁶². This custom StarDist
1115 model was trained for 300 epochs using 46 manually annotated paired images (image
1116 dimensions: (1024, 1024)) with a batch size of 2, an augmentation factor of 4 and a mae loss
1117 function. The StarDist “Versatile fluorescent nuclei” model was used as a training starting
1118 point. Key python packages used include TensorFlow (v 0.1.12), Keras (v 2.3.1), CSBdeep (v
1119 0.6.1), NumPy (v 1.19.5), Cuda (v 11.0.221). The training was accelerated using a Tesla
1120 P100GPU. Tracking was performed using a TrackMate script available here
1121 (https://github.com/HenriquesLab/ZeroCostDL4Mic/tree/master/Tools/Automated_tracking)
1122 and using the following settings: Linking max distance = 150 pixels, gap closing distance =
1123 20 pixels, Max frame gap =1. Cell tracks were combined in R using the script available here
1124 (https://github.com/HenriquesLab/ZeroCostDL4Mic/tree/master/Tools/Automated_tracking)
1125 and further analysed using the Motility Lab website (<http://www.motilitylab.net/>). The
1126 associated data used for analysis is available as Zenodo packages: the training dataset and the
1127 StarDist model used for the automated tracking ⁶⁹ and the archive source code used in the
1128 analyses ⁶⁵. Plots to visualize cell track speed and mean displacement were made using
1129 plotsofdata (1.05) ⁷⁰.

1130

1131 Scratch-wound migration assay

1132 After siRNA transfection, MDA-MB-231 cells were seeded into ibidi 2-well culture inserts
1133 placed in ibidi μ -dishes and allowed to become confluent. Prior to imaging, the culture inserts
1134 were carefully removed with forceps and the cells were washed twice with PBS. Next, warm
1135 medium was added to the cells, after which live imaging was started immediately (37 °C, 5 %
1136 CO₂). Cells were imaged using a Nikon Eclipse Ti2-E microscope with a 10x objective for 24
1137 h with a 20 minute imaging interval. Data was quantified using Fiji (ImageJ) by measuring
1138 the area of the closing gap between the cells at 0, 6, 8, 12, 16, and 18 h.

1139

1140 Invasion assay

1141 200 μ l of PureCol EZ gel (#5074; Advanced Biomatrix) was allowed to polymerize in 8 μ m
1142 inserts (#662638; Greiner Bio-One) for 1 h at 37 °C. Inserts were then inverted and 100 μ l of
1143 cell suspension (50000 cells) were seeded onto the outer face of the insert. Cells were
1144 allowed to adhere at 37 °C for 3 h. Inserts were then dipped sequentially into PBS and placed
1145 in serum-free medium. Medium supplemented with 10 % of FCS and 20 ng/ml of EGF was
1146 placed on top of the matrix and cells were allowed to invade the matrix for 72 h. Cells were

1147 then fixed using 4 % PFA for 2 h, permeabilized in 0.3 % Triton-X 100 for 1 h at room
1148 temperature, and stained overnight at 4 °C using Alexa Fluor 488 phalloidin. Invading cells
1149 were imaged using a confocal microscope (LSM880; Zeiss). Invasion was quantified using
1150 the area calculator plugin in ImageJ, measuring the fluorescence intensity of cells invading
1151 60 µm or more and expressing this as a percentage of the fluorescence intensity of all cells
1152 within the matrix.

1153

1154 Breast cancer tissue microarrays

1155 The study was approved by the Hospital District of Southwest Finland and Turku University
1156 Hospital (decision T012/015/19) and the use of tissue samples was approved by the Scientific
1157 Steering Group of Auria Biobank (decision AB19-4522). The study population consisted of
1158 243 patients with breast cancer diagnosed and treated in Turku University Hospital in 1998-
1159 2013. Informed consent was obtained from all the participants. All patients were treated with
1160 surgical resection or mastectomy and the archived formalin-fixed, paraffin-embedded tumor
1161 samples were used to form tissue microarrays (TMAs) that were prepared similarly as
1162 previously described ⁷¹. Briefly, the TMAs were prepared by punching a representative site of
1163 paraffin block of each tumor with either a 1 mm or a 1.5 mm diameter cylinder and using an
1164 automated tissue arrayer (TMA Grand Master, 3DHISTECH Ltd., Budapest, Hungary).

1165 The cohort consisted of 149 patients with triple negative and 89 patients with HER2-positive
1166 breast cancer diagnosed using the WHO classification criteria of tumors of the breast at the
1167 time of sampling. In addition, 4 patients with hormone receptor positive and 1 with non-
1168 neoplastic breast cancer were included in the TMAs. The cores were available from 225
1169 tumor centers, 121 tumor borders, 26 lymph node metastases and 127 tumor areas with
1170 inflammatory infiltrate.

1171 All relevant medical records of the patients were reviewed and information on tumor size,
1172 histological grade, hormone receptor status, Her2-oncogene, proliferation marker Ki-67 and
1173 axillary lymph node status were gathered. The follow-up time was until 31st March 2020 and
1174 the range of follow-up varied from 1 month to 22 years 3 months (mean 10 years 2 months).

1175

1176 Immunohistochemistry

1177 Immunohistochemistry was performed on TMAs comprising one or two tissue cores from
1178 each tumor site of each patient. The tissue samples were cut into 4 µm sections,

1179 deparaffinized and rehydrated with standard procedures. Heat-mediated antigen retrieval was
1180 done for all samples in citrate buffer (pH 6) in a pressure cooker (Decloaking chamber,
1181 Biocare Medical NxGen) for 20 min. Sections were stained in a semi-automatic Labvision
1182 autostainer (Thermo-Fisher Scientific), where they were washed with washing buffer (0.05 M
1183 Tris-HCl pH 7.6, 0.05 % Tween 20) and the endogenous enzymes were blocked with 3 %
1184 H₂O₂ Tris-HCl for 10 min. This was followed by a blocking step using Normal Antibody
1185 Diluent (NABD; Immunologic, BD09-125), incubation with the primary antibody (anti-
1186 Swip1, Atlas Antibodies, diluted 1:200) for 1 h, followed by washes and incubation with the
1187 secondary antibody (Goat anti-rabbit HRP, Immunologic DPVB110HRP) for 30 min.
1188 Samples were then washed and incubated with the DAB solution (Bright DAB, Immunologic
1189 BS04-110) for 10 min. After counterstain with Mayer's HTX, slides were dehydrated, cleared
1190 in xylene and mounted with Pertex. Antibody specificity was validated on agarose-embedded
1191 cell pellets post siRNA transfection (siCTRL, Swip1 siRNA #1 and Swip1 siRNA #2;
1192 Extended Data Fig. 10b).

1193 For each tumor sample, the percentage of cells with immunopositive signal (0-100%) in
1194 cytoplasm and in plasma membrane were scored. Samples with more than 80% of cells
1195 exhibiting positive staining were considered as having high Swip1, those with less than 30 %
1196 of cells as low Swip1 and samples in between were considered to have medium Swip1 levels.

1197

1198 Statistical analysis for clinical samples

1199 The statistical analysis was performed with SPSS Statistics 26 (IBM Corp., NY, USA). Two-
1200 tailed p values below 0.05 were considered statistically significant. The clinical parameters
1201 (age, tumor size and ki67) across Swip1 categories (<100 and 100, or <80 and ≥80) were
1202 evaluated with independent-samples double-sided Mann-Whitney U tests. The categorical
1203 parameters (grade and lymph node metastasis status) were compared with Chi Squared tests
1204 or Fisher's exact tests across Swip1 categories. Related-samples Wilcoxon signed rank test
1205 was used for paired comparisons of tumor centers and other core types. Patients with missing
1206 data were censored from the paired comparisons.

1207 Overall survival was compared between low and high percentage of immunopositive cells in
1208 the tumor center samples of Her2+ and TNBC patients using Kaplan-Meier plots and log-
1209 rank tests: the samples were divided into the following groups: <100% or 100% in the case of
1210 the cytoplasmic signal and <80% or ≥80% in the case of membranal Swip1 signal.

1211 The Cox proportional hazards regression analysis was used to assess the hazard ratio of tumor
1212 centers with high vs. lower Swip1 immunopositivity. In the case of non-proportional hazards,
1213 the weighted estimation of Cox regression was used⁷². The adjusted Cox analysis was
1214 performed relative to the clinical prognostic features. The analysis was performed with R
1215 Software for Statistical Computing (version 3.6.2, www.r-project.org) and survival (version
1216 3.1.8) and coxphw (version 4.0.2) packages. Survival differences were quantified as hazard
1217 ratios (HRs) with 95% confidence intervals (CI).

1218

1219 Statistics & Reproducibility

1220 Experiments were repeated at least 3 times to ensure reproducibility. All attempts at
1221 replication were successful. Key experiments were reproduced by different coauthors in
1222 different laboratories around the world. No statistical method was used to predetermine
1223 sample size. The standard in the field, a minimum of three, was selected for most
1224 experiments. No data were excluded from the analyses. For immunofluorescence analysis,
1225 randomization was ensured by taking representative pictures of different fields (or individual
1226 cells) from the same sample at different locations within the sample. Scoring of
1227 immunosignal in tissue samples was performed blindly by the pathologist. After scoring, the
1228 Biobank scientist correlated the scored values with the patient identifier and corresponding
1229 clinical information.

1230 The two-sided Significance B test was used to identify relevant interactors of Rab21 from the
1231 proteomics dataset. No multiple hypothesis correction method was applied, due to the small
1232 number of selected proteins for the statistical analysis. Abundance bins were defined by
1233 including 1000 proteins in a subsequent order.

1234 The GraphPad Prism software and two-tailed Student's t test (paired or unpaired, as
1235 appropriate) was used for statistical analysis of *in vitro* experiments. When data were not
1236 normally distributed, a two-sided Mann-Whitney test was used. For the ELISA-based
1237 trafficking assay and the scratch-wound migration assay, statistical significance was
1238 determined using multiple comparison t-tests for paired data, with the post hoc Holm-Sidak
1239 method, with alpha=5.000%. Each row was analyzed individually, without assuming a
1240 consistent SD.

1241 The number of cells analyzed for experiments in Figures 4, 5 and 7 is defined as follows:

1242 Figure 4. Number of cells analyzed over 3 independent experiments: (a) siCTRL, 86, 101,
1243 110 and 78; Swip1 siRNA#1, 104, 98, 102 and 106; from left to right. (b) siCTRL+GFP, 153;

1244 siCTRL+GFP-Swip1, 186; siSwip1+GFP, 136 and siSwip1+GFP-Swip1, 196. (c) siCTRL,
1245 107, Swip1 siRNA#1, 116, siRab21, 122 (d) α 2 integrin-WT, 70 and mutant α 2 integrin-AA,
1246 76. (e) siCTRL, 50 and siRab21, 56 (h) siCTRL+GFP, 157; siCTRL+GFP-Swip1, 289;
1247 siIRSp53+GFP, 108 and siIRSp53+GFP-Swip1, 136. (i) GFP, 106 and GFP-Swip1, 111.

1248 Figure 5. Number of cells analyzed over 3 independent experiments: (a) Dextran-FITC, 18
1249 and 21 and β 1-integrin-A488, 22 and 21. (b) siCTRL, 160; Swip1 siRNA#1, 157; Swip1
1250 siRNA#2, 160; siCTRL, 121; IRSp53 siRNA#1, 177 and IRSp53 siRNA#2, 121. (c) siCTRL,
1251 152; Swip1 siRNA#1, 125 and IRSp53 siRNA#1, 92. (d) For BT-20 12G10 and MHC1
1252 uptake, respectively, siCTRL, 79 & 91; Swip1 siRNA#1, 76 & 91; Swip1 siRNA#2, 66 & 75.
1253 For MDA-MB-468 12G10 and MHC1 uptake, respectively, siCTRL, 134 & 155; Swip1
1254 siRNA#1, 98 & 156; Swip1 siRNA#2, 98 & 135 (e) For dextran uptake, without (-) or with
1255 (+) hypotonic shock, respectively: siCTRL, 227 & 220; Swip1 siRNA#1, 208 & 186; Swip1
1256 siRNA#2, 208 & 187. For β 1-integrin uptake, without (-) or with (+) hypotonic shock,
1257 respectively: siCTRL, 195 & 191; Swip1 siRNA#1, 208 & 181; Swip1 siRNA#2, 181 & 139.
1258 (f) siCTRL, 50 and siRab21, 56.

1259 Figure 7. Number of cells analyzed over 3 independent experiments: (a) collagen I, 65, 76 &
1260 67; fibronectin, 65, 75 & 62; laminin-1, 62, 66 & 73 for siCTRL, siSwip1 siRNA #1 and
1261 siRNA #2, respectively. (b) 18 cells per condition; FAs analyzed: siCTRL, 861 & 764; and
1262 siSwip1, 1014 & 1024 for assembly and disassembly, respectively. (c) 20 cells per condition,
1263 697 BiFC puncta and 1364 randomly distributed puncta.

1264

1265 **Data Availability:**

1266 The data that support the findings of this study are available within the paper [and its
1267 supplementary information files] or from the corresponding author upon reasonable request. The
1268 proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner
1269 repository with the dataset identifier PXD016478.

1270

1271

1272 **Code Availability**

1273 Custom code written to perform the migration analyses has been deposited to Zenodo
1274 (<https://zenodo.org/record/4812018#.YK5JdHUzaV4>). Deep Learning model used to analyze the
1275 cell migration data has also been deposited to Zenodo
1276 (<https://zenodo.org/record/4811213#.YK5FGnUzaV4>).

1277




1278




1279

1280 **Methods References**



- 1281 51. Paul, F. E., Hosp, F. & Selbach, M. Analyzing protein-protein interactions by
1282 quantitative mass spectrometry. *Methods San Diego Calif* **54**, 387–395 (2011).
- 1283 52. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates,
1284 individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.
1285 *Nat. Biotechnol.* **26**, 1367–1372 (2008).
- 1286 53. Borchers, H. W. pracma: Practical Numerical Math Functions. (2019).
- 1287 54. Perez-Riverol, Y. *et al.* The PRIDE database and related tools and resources in 2019:
1288 improving support for quantification data. *Nucleic Acids Res.* **47**, D442–D450 (2019).
- 1289 55. Ovesný, M., Křížek, P., Borkovec, J., Svindrych, Z. & Hagen, G. M.
1290 ThunderSTORM: a comprehensive ImageJ plug-in for PALM and STORM data analysis
1291 and super-resolution imaging. *Bioinforma. Oxf. Engl.* **30**, 2389–2390 (2014).
- 1292 56. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat.*
1293 *Methods* **9**, 676–682 (2012).
- 1294 57. Martens, K. J. A., Bader, A. N., Baas, S., Rieger, B. & Hohlbein, J. Phasor based
1295 single-molecule localization microscopy in 3D (pSMLM-3D): An algorithm for MHz
1296 localization rates using standard CPUs. *J. Chem. Phys.* **148**, 123311 (2018).
- 1297 58. Farage, E. & Caswell, P. T. Quantitative Analysis of Integrin Trafficking. *Methods*
1298 *Mol. Biol. Clifton NJ* **2217**, 251–263 (2021).
- 1299 59. Arjonen, A., Alanko, J., Veltel, S. & Ivaska, J. Distinct recycling of active and
1300 inactive β 1 integrins. *Traffic Cph. Den.* **13**, 610–625 (2012).
- 1301 60. Berginski, M. E. & Gomez, S. M. The Focal Adhesion Analysis Server: a web tool for
1302 analyzing focal adhesion dynamics. *F1000Research* **2**, 68 (2013).
- 1303 61. Krull, A., Buchholz, T.-O. & Jug, F. Noise2Void - Learning Denoising from Single
1304 Noisy Images. *ArXiv181110980 Cs* (2019).
- 1305 62. von Chamier, L. *et al.* Democratising deep learning for microscopy with
1306 ZeroCostDL4Mic. *Nat. Commun.* **12**, 2276 (2021).
- 1307 63. Arganda-Carreras, I. *et al.* Trainable Weka Segmentation: a machine learning tool for
1308 microscopy pixel classification. *Bioinformatics* **33**, 2424–2426 (2017).
- 1309 64. Gilles, J.-F., Dos Santos, M., Boudier, T., Bolte, S. & Heck, N. DiAna, an ImageJ tool
1310 for object-based 3D co-localization and distance analysis. *Methods San Diego Calif* **115**,
1311 55–64 (2017).
- 1312 65. Jacquemet, G. *Archived source code for Cargo-specific recruitment in clathrin and*
1313 *dynammin-independent endocytosis.* (Zenodo, 2021). doi:10.5281/zenodo.4812018.


- 1314 66. Fazeli, E. *et al.* Automated cell tracking using StarDist and TrackMate.
1315 *F1000Research* **9**, 1279 (2020).
- 1316 67. Tinevez, J.-Y. *et al.* TrackMate: An open and extensible platform for single-particle
1317 tracking. *Methods San Diego Calif* **115**, 80–90 (2017).
- 1318 68. Schmidt, U., Weigert, M., Broaddus, C. & Myers, G. Cell Detection with Star-Convex
1319 Polygons. in *Medical Image Computing and Computer Assisted Intervention – MICCAI*
1320 *2018* (eds. Frangi, A. F., Schnabel, J. A., Davatzikos, C., Alberola-López, C. &
1321 Fichtinger, G.) 265–273 (Springer International Publishing, 2018). doi:10.1007/978-3-
1322 030-00934-2_30.
- 1323 69. Al-Akhrass, H., Ivaska, J. & Jacquemet, G. Stardist model and training dataset for
1324 automated tracking of MDA-MB-231 and BT20 cells. (2021)
1325 doi:10.5281/zenodo.4811213.
- 1326 70. Postma, M. & Goedhart, J. PlotsOfData—A web app for visualizing data together
1327 with their summaries. *PLOS Biol.* **17**, e3000202 (2019).
- 1328 71. Heuser, V. D. *et al.* Formin Proteins FHOD1 and INF2 in Triple-Negative Breast
1329 Cancer: Association With Basal Markers and Functional Activities. *Breast Cancer Basic*
1330 *Clin. Res.* **12**, 1178223418792247 (2018).
- 1331 72. Dunkler, D., Ploner, M., Schemper, M. & Heinze, G. Weighted Cox Regression Using
1332 the R Package coxphw. *J. Stat. Softw.* **84**, 1–26 (2018).




















d **GFP-Rab21 mScarlet-I-Swip1**































Swip1 staining	TNBC samples		HER2+ samples	
	#	%	#	%
High	87	65.4%	66	75.0%
Medium	20	15.0%	9	10.2%
Low	26	19.6%	13	14.8%
Total	133	100%	88	100%

















a**Figure 2e full picture and ROI****Figure 3d full pictures and ROI****c****Colocalization with Scarlet-Swip1****b****Figure 2d full picture**










a EFHD2 mRNA level



		EFHD2 mRNA level				total samples	p
		< median		> median			
		# samples	% samples	# samples	% samples		
molecular subtype	HER2+	10	34.5%	19	65.5%	29	0.002
	luminal	72	58.5%	51	41.5%	123	
	TNBC	11	29.7%	26	70.3%	37	
total						189	
grading	1	12	60.0%	8	40.0%	20	0.049
	2	47	58.8%	33	41.3%	80	
	3	38	41.3%	54	58.7%	92	
total						192	

b Swip1 staining



c

Membranal Swip1	TNBC samples	
	#	%
High	20	15.0%
Medium	19	14.3%
Low	94	70.7%
Total	133	100%



Moreno-Layseca et al., Cargo-specific recruitment in clathrin- and dynamin-independent endocytosis

Supplementary Information:

Supplementary Figure 1. Representative raw flow cytometry data and gating strategy for Extended Data Figure 6d.

**MDA-MB-231 EGFR cell surface FACS
(anti-EGFR+Alexa-647 anti-mouse)**

